

Human polyomaviruses and cancer: an overview

José Carlos Mann Prado, Telma Alves Monezi, Aline Teixeira Amorim, Vanesca Lino, Andressa Paladino, Enrique Boccardo*

Departamento de Microbiologia, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP, BR.

Prado JC, Monezi TA, Amorim AT, Lino V, Paladino A, Boccardo E. Human polyomaviruses and cancer: an overview. Clinics. 2018;73(suppl 1):e558s

*Corresponding author. E-mail: eboccardo@usp.br

The name of the family *Polyomaviridae*, derives from the early observation that cells infected with murine polyomavirus induced multiple (*poly*) tumors (*omas*) in immunocompromised mice. Subsequent studies showed that many members of this family exhibit the capacity of mediating cell transformation and tumorigenesis in different experimental models. The transformation process mediated by these viruses is driven by viral pleiotropic regulatory proteins called T (tumor) antigens. Similar to other viral oncoproteins T antigens target cellular regulatory factors to favor cell proliferation, immune evasion and downregulation of apoptosis. The first two human polyomaviruses were isolated over 45 years ago. However, recent advances in the DNA sequencing technologies led to the rapid identification of additional twelve new polyomaviruses in different human samples. Many of these viruses establish chronic infections and have been associated with conditions in immunosuppressed individuals, particularly in organ transplant recipients. This has been associated to viral reactivation due to the immunosuppressant therapy applied to these patients. Four polyomaviruses namely, Merkel cell polyomavirus (MCPyV), Trichodysplasia spinulosa polyomavirus (TSPyV), John Cunningham Polyomavirus (JCPyV) and BK polyomavirus (BKPyV) have been associated with the development of specific malignant tumors. However, present evidence only supports the role of MCPyV as a carcinogen to humans. In the present review we present a summarized discussion on the current knowledge concerning the role of MCPyV, TSPyV, JCPyV and BKPyV in human cancers.

KEYWORDS: MCPyV; BKPyV; JCPyV; TSPyV; Human cancer.

■ INTRODUCTION

Polyomaviruses (PyVs) are icosahedral, nonenveloped viruses that are approximately 45 nm in size. The capsid is composed of 72 pentameric capsomers and surrounds a circular, double-stranded viral DNA genome that is approximately 5,5 kbp. Inside the virion, the DNA is associated with the cellular histones H2A, H2B, H3 and H4, forming the viral minichromosome. In addition, inside the cell, the minichromosome is found to be associated with histone H1 (1). These viruses are relatively resistant to treatment with formalin and are not affected by organic solvents (2).

Currently, the International Committee on Taxonomy of Viruses (ICTV) has divided the *Polyomaviridae* family into 5 genera: *Alphapolyomavirus*, with 37 species that infect animals and humans, including human PyVs (HPyVs) 5, 8, 9, 12 and 13; *Betapolyomavirus*, with 29 species that infect animals and humans, including HPyVs 1 and 4; *Deltapolyomavirus* with only HPyVs 6, 7, 10 and 11; *Gammapolyomavirus*, with seven

animal virus species, including PyVs that infect birds; and, finally, an unassigned genus that contain three species of animal PyVs (3,4).

Biology of polyomaviruses

The genomes of PyVs can be divided into three regions: the control region; the early region, which encodes early proteins; and the late region, which encodes late proteins with structural function. The control region contains the origin of replication and the promoters that regulate the expression of early and late genes. However, this region does not encode any protein or functional RNA. This region is involved in the regulation of the viral life cycle by modulating replication and transcription. Both strands of the PyV DNA code for proteins. Early genes are expressed from one strand immediately after infection. On the other hand, late genes are expressed from the opposite strand after viral genome replication. The mRNA transcribed from both early and late regions exist in at least two isoforms due to alternative processing. In addition, the expression of a viral microRNA has been observed in the John Cunningham polyomavirus (JCPyV), BK polyomavirus (BKPyV) and Merkel cell polyomavirus (MCPyV) (5,6). This microRNA is encoded by the DNA strand complementary to the large T antigen (see below) and, at least in MCPyV, this RNA seems to regulate the expression of this viral protein (5).

The proteins encoded by the early genes are involved in the regulation of viral transcription and genome replication. These proteins are known as "T antigens" and received this name because they were recognized by antibodies from

Copyright © 2018 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

No potential conflict of interest was reported.

Received for publication on January 4, 2018. **Accepted for publication on** May 15, 2018

Commemorative Edition: 10 years of ICESP

DOI: 10.6061/clinics/2018/e558s



rodents bearing tumors (7). Different T antigen isoforms exist and are named depending on the viral species from which they originate. The transforming potential of the viral group is directly related to the expression of T antigens and was initially established in studies using simian virus 40 (SV40) (8). The large T (LT) antigen is a nuclear protein that is approximately 700 amino acids. However, alterations in its phosphorylation pattern may change the location of this protein within the cell (9,10). The LT antigen regulates both viral transcription and genome replication (11). In addition, the LT antigen as well as the other T antigen isoforms expressed in human and animal PyVs are pleiotropic proteins that affect the function and expression of several cellular proteins involved in the regulation of cell proliferation (see below). The neutralization of the functions of these proteins is critical for the induction of the entry of the host cell into the cell cycle, making the DNA replication machinery available and allowing viral genome replication (12-15).

The late region harbors the genes that encode structural proteins found in the viral capsid, such as VP1 and VP2. Some species also express the structural proteins VP3 and VP4. VP2 and VP3 are important for viral entry into the host cell. However, the role of VP4 during the viral life cycle remains a matter of debate. Previous studies have suggested that VP4 acts as a viroporin to disrupt the nuclear envelope and mediate viral release (16-19). However, in a recent study, Henriksen et al. showed that human renal proximal tubule epithelial cells transfected with BKPyV genomes carrying start codon substitutions in VP4, predicted to abolish the production of this protein, released comparable amounts of viral particles in the supernatant as cells transfected with WT genomes (20). It is clear that additional studies are needed to determine the role of VP4 in PyV biology. In addition, some PyVs, including JCPyV, BKPyV and SV40, present an open reading frame (ORF) that encodes a regulatory cytoplasmic protein named agnoprotein (21). The involvement of agnoprotein in viral release has been suggested in species that express this protein, including SV40, JCPyV and BKPyV (22).

Studies conducted during the past two decades have shown that the expression of VP1 in different systems leads to the production of structures called virus-like particles (VLPs), which are similar to the viral capsid (23-27). After being expressed, the structural proteins accumulate in the cellular nucleus, contributing to the mounting of the virion. These proteins are found in different amounts in viral capsids, with VP1 being the major protein in the formation of pentamers. The carboxy end of VP1 extends outside the pentamer and interacts with surrounding pentamers. These interactions, mediated by VP1 together with Ca^{2+} and disulfide bonds, contribute to the stabilization of the capsomers and capsid structure (2).

The mechanism of viral entry into the host cell seems to depend on the virus and cell type under study. For instance, cell internalization via caveolin- or clathrin-dependent endocytosis, as well as entry via other mechanisms, has been previously described (28,29). Once in the cytoplasm, the viral capsid suffers alterations that expose the nuclear localization signals present in proteins VP2 and VP3 and mediate nuclear import. After reaching the nucleus, the capsid is completely dismounted, and the viral genome is exposed and maintained in the episomal form. Next, the early region is transcribed to produce an mRNA molecule that, after processing, will generate the large T antigen and its other isoforms. The LT antigen protein will first mediate viral genome replication. This event

may also be regulated by epigenetic mechanisms due to the association of viral DNA with cellular histones (30). Only after genome amplification will the LT antigen promote the transcription of the late region to express the structural proteins. Infective virions are mounted in the nucleus, and the release of these virions may depend on the occurrence of cell lysis (2,31).

The majority of PyV infections are asymptomatic; however, these infections may cause alterations in cell cultures and induce tumors in immunocompromised laboratory animals, including newborn mice. The transforming potential of PyVs has been demonstrated *in vitro* using cells from different organisms (32). Early studies conducted in immunocompromised animals injected with murine polyomavirus (MuPyV)-infected cells showed the formation of multiple (*poly*) tumors (*omas*) and served to name the group (7).

Human polyomaviruses

The discovery and characterization of HPyVs occurred in different technological contexts. In 1971, two isolates were described, and for decades, these species remained the only members of the family that infected humans (33,34). It was not until 2007, and only after major advances in DNA sequencing technologies, that other twelve PyVs were identified in human samples, increasing the total number of HPyVs to fourteen (14,35-44). The timeline of HPyV discovery is summarized in Figure 1.

Serological studies have shown that exposure to most HPyVs occurs early in life and that infection prevalence in adults may be high (45). Interestingly, immunocompromised individuals exhibit higher viral loads of these agents suggesting that immunocompromised individuals are more susceptible to reactivation of these viruses (14,46-49). Among the PyVs that affect humans and are associated with important diseases in immunocompromised individuals, the most relevant are JCPyV, BKPyV, MCPyV and Trichodysplasia spinulosa PyV (TSPyV). These PyVs are ubiquitous and are highly prevalent in the normal human population. In general, infection by these agents is asymptomatic in healthy individuals, with prevalence values as high as 80% in adults, as determined by serological studies (27,50). On the other hand, in immunocompromised persons, infection with BKPyV is associated with the development of nephropathies and hemorrhagic cystitis, while infection with JCPyV is associated with progressive multifocal leukoencephalopathy (PML). In addition, MCPyV is associated with the development of Merkel cell carcinoma (MCC) and is considered a group 2A carcinogen (probably carcinogenic to humans) by the International Agency for Research on Cancer (51).

It is accepted that PyV-associated tumors develop after the interruption of the viral life cycle. This may be caused by accidental viral integration into the cellular genome. In the case of MCPyV and BKPyV, viral cycle interruption may be caused by rupture of the VP1 gene (52,53) or by loss of the carboxy-terminal domain of the LT antigen due to nonsense mutations. This domain of the LT antigen is needed for the normal cycle to promote viral genome replication (52,37). Therefore, viral replication is interrupted while truncated versions of the LT antigen and its isoforms are expressed (52).

The presence of the LT antigen is a universal characteristic of the members of the *Polyomaviridae* family. LT antigens share high identity between the members of the PyV genus, which allows recognition by cross-hybridization in western blots performed with a few specific antibodies (54).




Figure 1 - Timeline of the discovery of human polyomaviruses. The timeline shows the name of the virus, the year of discovery and the type of sample from which the virus was isolated. For complete references, see the text. BKV or BKPyV, human polyomavirus BK or human polyomavirus 1; JCV or JCPyV, John Cunningham or JC polyomavirus or human polyomavirus 2; KIPyV, Karolinska Institute polyomavirus or human polyomavirus 3; WUPyV, Washington University polyomavirus or human polyomavirus 4; MCPyV, Merkel cell polyomavirus or human polyomavirus 5; HPyV6, human polyomavirus 6; HPyV7, human polyomavirus 7; TSPyV, Trichodysplasia spinulosa polyomavirus or human polyomavirus 8; HPyV9, human polyomavirus 9; MWPyV, Malawi polyomavirus or human polyomavirus 10; STLPyV Saint Louis polyomavirus or human polyomavirus 11; HPyV12, human polyomavirus 12; NJPyV, New Jersey polyomavirus or human polyomavirus 13; LIPyV, Lyon IARC polyomavirus or human polyomavirus 14.

The N-terminal region of this protein contains a DnaJ domain, which contributes to viral replication and mediates the binding of the cellular chaperone HSc70. This protein also contains an LXCXE motif that binds the members of the retinoblastoma protein family pRb, p107 and p130. Together DnaJ and LXCXE disturb the pRb/E2F complexes, promoting the progression of the cell cycle (11). The C-terminal domain of the LT antigen harbors a conserved threonine residue that, when phosphorylated, competes with cyclin E1 and Myc to bind to FBXW7. The protein FBXW7 (F-box) is part of the ubiquitin ligase complex formed by Skp1/culin/F-box (SCF). As such, LT prevents the degradation of cyclin E1 and Myc and contributes to cell growth and proliferation (31).

The LT antigen also presents a nuclear localization sequence (NLS), an origin-binding domain (OBD) and a helicase domain. The OBD and the helicase domain are critical for viral genome replication (55). Finally, LT antigens from many, but not all, HPyVs exhibit a p53-binding domain (56,57). The colocalization of p53 and the LT antigen has been demonstrated in the cytoplasm of cultured cells of BKPyV-positive neuroblastoma and prostate cancer (58,59). It is believed that this interaction may block the expression of p53-regulated genes in response to DNA damage (57). Another cellular target of early PyV proteins is the phosphatase PP2A (60). This protein is inactivated by T antigens from SV40, JCPyV and MCPyV (59). PP2A is a critical regulator of the mitogen-activated protein kinase (MAPK) signaling cascade and has many functions. This protein contributes to the control of cellular metabolism by regulating the activities of different enzymes involved in glycolysis, lipid metabolism and catecholamine synthesis (61). In addition, this protein regulates various critical processes, such as cell cycle progression, DNA replication and transcription, protein translation, signal transduction, cytoskeletal dynamics, cell mobility and apoptosis. As such, PP2A plays an important role in cell transformation and cancer (62-65).

Most HPyVs have the potential to cause nonneoplastic diseases in the context of immunosuppression (54). However, this association has only been confirmed for a few of these viruses. Among the 4 PyVs associated with diseases in immunosuppressed humans, two are associated with proliferative diseases of the skin. MCPyV is associated with MCC, while TSPyV is the etiological factor for Trichodysplasia spinulosa (TS). The two other viruses are JCPyV, which is associated with PML, and BKPyV, which is a leading cause of chronic dysfunction in renal transplant patients, urethral stenosis and nephropathy. The main characteristics of these viruses will be presented in the next sections. Moreover, the cell transforming potential exhibited by different HPyV proteins *in vitro* raises the intriguing possibility that some of these agents, in addition to MCPyV, may be associated with specific human cancers. Therefore, several studies conducted by different groups around the world have addressed the presence of all HPyVs in different human tumors. Table 1 presents a comprehensive summary of the main results obtained.

Merkel cell polyomavirus and Merkel cell carcinoma

In 2008, the identification of the fifth HPyV, detected in samples of MCC, was reported, and this virus was named MCPyV. The authors performed digital transcriptome subtraction (DTS) in MCC samples and identified one sequence that exhibited no similarity with human transcripts. In-depth analysis of the transcript using nucleotide databases showed that this sequence was related to the T antigen sequence from simian lymphotropic polyomavirus (LPyV) and BKPyV. The viral genome, which was detected in 80% of the MCC samples, was amplified by *primer walking* and sequenced. The study also showed that in most of the MCPyV-positive tumors, the viral DNA exhibited a clonal integration pattern within the cell genome. The same integration pattern detected



Table 1 - Continued.

PyVs	Solid tumors										Skin cancer			Blood cells		Sarcoma				Urinary tract				Gynecologic tract			Digestive tract			Oral cavity			CNS		Method	Reference				
	Lung	Head and neck	Breast	Uveal	Thymus	Kidney	Liver	Thyroid	Keratoacanthomas	SCC,BCC,melanoma	Skin cancer	Spitz naevus	Leukemia	Lymphoma	Soft tissue	Ewing's	Osteosarcoma	Sarcoma	Kaposi	Prostate	Urinary tract	Urethral	Bladder	Ureter	Ovary	Cervix	Gynecologic tract	Stomach	Large bowel	Colorectal	Digestive System	Tonsils	Oral cavity	Brain			Meningiomas	Neuroblastoma	CNS	
HPyV3 (KIPyV)	0 (0.20)	0 (0.183)	0 (0.123)																	0 (0.109)	0 (0.137)	0 (0.168)											0 (0.59)				qPCR	Teramoto et al., 2011 (224)		
	0 (0.19)																																			PCR	Colombara et al., 2016 (225)			
	0 (0.2236)																																			PCR	Coxson et al., 2014 (215)			
	0 (0.086)																																			PCR	Guind et al., 2009 (226)			
	0 (0.52)																																			qPCR	Coxson et al., 2018 (227)			
	0 (0.19)																																				qPCR	Coxson et al., 2018 (227)		
	0 (0.2236)																																				qPCR	Coxson et al., 2018 (227)		
	0 (0.32)																																					qPCR	Coxson et al., 2018 (227)	
	0 (0.19)																																					qPCR	Coxson et al., 2018 (227)	
	0 (0.32)																																						qPCR	Coxson et al., 2018 (227)
	0 (0.32)																																					qPCR	Coxson et al., 2018 (227)	
HPyV4 (WUPyV)	0 (0.19)																			0 (0.109)	0 (0.137)	0 (0.168)														PCR	Guind et al., 2009 (226)			
	0 (0.19)																			0 (0.109)	0 (0.137)	0 (0.168)															qPCR	Coxson et al., 2018 (227)		
	0 (0.2236)																																				PCR	Herberhold et al., 2017 (205)		
	0 (0.19)																																				qPCR	Coxson et al., 2018 (227)		
	0 (0.2236)																				0 (0.109)	0 (0.137)	0 (0.168)														qPCR	Herberhold et al., 2017 (205)		
	0 (0.19)																																				qPCR	Coxson et al., 2018 (227)		
	0 (0.2236)																																					qPCR	Herberhold et al., 2017 (205)	
	0 (0.19)																																					qPCR	Coxson et al., 2018 (227)	
	0 (0.2236)																																						qPCR	Herberhold et al., 2017 (205)
	0 (0.19)																																						qPCR	Coxson et al., 2018 (227)
	0 (0.2236)																																						qPCR	Herberhold et al., 2017 (205)



Table 1 - Continued.

PVs	Solid tumors							Skin cancer			Blood cells		Sarcoma			Urinary tract						Digestive tract			Oral cavity			CNS			Method	Reference													
	Lung	Head and neck	Breast	Uveal	Thymus	Kidney	Liver	Thyroid	Keratoacanthomas	SCC,BCC,melanoma	Skin cancer	Spitz naevus	Leukemia	Lymphoma	Soft tissue	Ewings	Osteosarcoma	Sarcoma	Kaposi	Frostbite	Urinary tract	Urethral	Bladder	Ureter	Ovary	Cervix	Gynecologic tract	Stomach	Large bowel	Colorectal			Digestive System	Tonsils	Oral cavity	Brain	Meningiomas	Neuroblastoma	CNS						
HPV10 (MWPVV)	0 (0.100)																					0 (0.137)						0 (0.28)		18 (7.28)	0 (0.65)							qPCR	Cosma et al., 2016 (227)						
	0 (0.236)		0 (0.65)						0 (0.50)	0 (0.50)																												PCR	Heberhold et al., 2017 (205)						
																																							IHC	Toplan et al., 2016 (54)					
HPV11 (STLPV)	0 (0.100)									0 (0.37)												0 (0.137)						0 (0.28)		0 (0.64)											qPCR	Cosma et al., 2016 (227)			
	0 (0.236)		0 (0.65)								0 (0.50)												0 (0.137)					0 (0.28)		0 (0.64)											PCR	Heberhold et al., 2017 (205)			
																							0 (0.137)					0 (0.28)		0 (0.64)											IHC	Toplan et al., 2016 (54)			
HPV12	0 (0.236)		0 (0.65)							0 (0.50)												0 (0.137)						0 (0.28)		0 (0.64)												PCR	Heberhold et al., 2017 (205)		
																							0 (0.137)					0 (0.28)		0 (0.64)												IHC	Toplan et al., 2016 (54)		
HPV13 (NJPV)	0 (0.236)		0 (0.65)							0 (0.50)												0 (0.137)						0 (0.28)		0 (0.64)														PCR	Heberhold et al., 2017 (205)
																							0 (0.137)					0 (0.28)		0 (0.64)														IHC	Toplan et al., 2016 (54)

PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; SB, Southern blot hybridization; IHC, immunohistochemistry; IFA, immunofluorescence; ISH, *in situ* hybridization; DDRk, DNA-DNA reassociation kinetics

Sample description and number (when available):

- a) (18) Breast; (8) rectal; (7) liver; (3) brain; (3) ovarian; (2) cervical carcinoma; (2) plural mesothelioma; (2) testicular carcinoma; (1) laryngeal carcinoma; (1) bladder; (1) non-small cell lung carcinoma (NSCLC); (1) penis sarcoma; and (2) synovial sarcoma.
- b) (21) Squamous cell carcinoma (SCC); (18) basal cell carcinoma (BCC); (20) melanoma; and (20) MCV-neg MCC.
- c) (86) SCC; (109) BCC; (45) tricoblastoma; (59) keratoacanthoma.
- d) BCC; SCC; keratoacanthoma; microcystic adnexal carcinoma; atypical fibroxanthoma; facultative SCC precursor lesions; actinic keratosis (AK); and SCC *in situ* (SCCis).
- e) Only melanoma tissues from patients treated with serine/threonine-protein kinase B-raf (BRAF) inhibitors.
- f) Skin no MCC - BCC, melanoma and other.
- g) Tumors from 8 histological types.
- h) Tumors from 11 histological types (total n = 24 and 21 for BKPVV and JCPV, respectively).
- i) (13) Primary tumors, (4) post treatment and (1) liver metastasis.
- k) Range of prevalence from different studies using serological and molecular assays.




Figure 2 - Schematic representation of the genomes of BKPyV, JCK, MCPyV and TSPyV. The early and late regions (gray) are transcribed from opposite strands of the genome. The early region is transcribed in the counterclockwise direction and harbors the genes coding for the different T antigen isoforms as indicated. The late region expresses the structural genes (VPs) and the agnoprotein ORF (when present). BKPyV, JCV and MCPyV express a microRNA from the opposite strand of the early region. The noncoding control region (NCCR) contains the origin of genome replication and the promoters for the regulation of transcription. For details, see text.

in primary tumors was observed in the derived metastases, supporting the notion that viral integration preceded the clonal expansion of tumor (37).

MCC, a rare and aggressive neoplasia, was described in 1972 by Tokier as a trabecular carcinoma of the skin (66). Data from the Netherlands show an incidence rate of 0,35 cases per 100.000 per year (0,35/100.000), while the incidence in the USA is 0,24/100.000 (67,68). On the other hand, in Queensland (Australia), where most habitants are Caucasian, the incidence increases to 1,6/100.000 (69). This tumor is more prevalent in men (61% of the cases) than in women, particularly in white individuals older than 65 years (68-70). This pathology is well described by the acronym AEIOU: “Asymptomatic/lack of tenderness, Expanding rapidly, Immune suppression, Older than age 50, and UV-exposed site on a person with fair skin” (71). MCC occurs as fast-growing reddish-blue nodules located mainly over soft tissues, sometimes with telangiectasia, in areas exposed to intense solar radiation. The occurrence of MCC varies from 41% to 50% in the head and neck, 32% to 38% in the limbs and 12% to 14% in the trunk of the body (72). In addition, MCC can be detected in anatomic areas with low UV exposure, such as genitalia and mucosa (71). Interestingly, a retrospective study conducted in the USA showed that MCC cases in black people occur mainly at the extremities of the

inferior limbs (73). The ultimate diagnosis of MCC is given by histopathological analysis of biopsies. This tumor presents small ovoid cells with hyperchromatic nuclei, which are characteristic of neuroendocrine tumors. The tumor architecture may be trabecular, nodular or diffuse (74). The best immunohistochemical markers for this pathology are neurofilaments and cytokeratin 20 (75).

Merkel cell polyomavirus biology and epidemiology.

The MCPyV genome comprises 5387 bp (isolate MCC350, EU375803) and exhibits the characteristic organization of the family (Figure 2). The early region of this virus expresses the large T (LT), small (sT), and 57kT antigens (76). In addition, in 2013, the existence of a fourth ORF, expressed from an alternative transcription initiation site located in the second exon of the gene coding for the LT antigen was described. The protein coded by this gene is called alternate frame of the large T ORF (ALTO); this protein is expressed in replicating infected cells and remains in the cytosol. The role of this protein in the viral cycle and associated diseases has not been determined. Intriguingly, the ORF that encodes this protein has been found to be mutated in tumor tissues, suggesting that this protein may play a role in viral pathogenesis (77). The importance of the LT antigen in the pathology mediated by this virus is highlighted by the fact that silencing of this



antigen in MCPyV-positive MCC-derived cells inhibits cell growth and induces senescence (78). Several studies have demonstrated that MCPyV genomes present in tumors exhibit mutations in the 3' region of the gene encoding the LT antigen, mainly at the region upstream of the helicase domain and downstream of the gene encoding the sT antigen (53,79-81). The accumulation of mutations in this portion of the LT antigen is important in the process of carcinogenesis since these mutations downregulate viral replication and viral load, allowing immune evasion while retaining the ability to promote unscheduled cell proliferation. This phenomenon is possible because the mutated form of the LT antigen always preserves the domains that are involved in interactions with cellular factors, including the domain that targets pRb (82). The sT antigen, a 186-amino-acid protein, harbors the site for PP2A binding. This site is conserved among PyVs and plays a role in cellular transformation (60). In addition, the sT antigen promotes LT-antigen-dependent MCV genome replication by sequestering the F-box and WD repeat domain containing 7 (FBXW7) component of the Skp, Cullin, F-box (SCF)-containing ubiquitin ligase responsible for LT antigen degradation by the proteasome (76,83). The amino acids at position 91 to 95 of the sT antigen are required for this function and define the large T stabilization domain (LSD). Mutation of the LSD in the sT antigen leads to downregulation of the LT antigen and prevents viral genome replication. Mutations in this domain also prevent rodent cell transformation and induction of cellular oncoproteins, including c-Myc and cyclin E, by the sT antigen (84). Moreover, *in vitro* and *in vivo* observations indicate that LSD integrity is required for sT mediated induction of supernumerary centrosomes, appearance of aneuploid cells, accumulation of chromosomal breaks and micronuclei (85). Importantly, sustained expression of the sT antigen in MCPyV is required for tumor cell proliferation, which has been linked to sT-antigen-mediated stabilization of the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which leads to increased cap-dependent translation in infected cells (86). Moreover, a recent study conducted using an *in vivo* model of MCC showed that expression of the sT antigen with an intact LSD domain was critical for tumor initiation. On the other hand, coexpression of LT did not affect the frequency of tumor establishment (87). Finally, the MCPyV sT antigen is more frequently detected in human MCC tumors than the LT antigen. These observations suggest a critical role for the sT antigen in MCPyV-mediated carcinogenesis. As previously mentioned, MCPyV integration into the genome of the host cell, which interrupts normal viral cycle regulation, is a critical step in MCC development (76). To date, there has been no report of MCCs harboring MCPyV DNA in the episomal state. Importantly, a truncated form of the LT antigen or its complete smaller isoforms continue to be expressed, altering cell homeostasis (88-91).

Finally, the MCPyV early region expresses a microRNA with no identified cellular target but complementary to the 3' portion of the LT antigen, suggesting the involvement of this microRNA in the regulation of the expression of the viral protein (5).

The late region harbors the genes that encode the structural proteins VP1, VP2 and VP3. Interestingly, VP3 is not detected in MCPyV-infected cells or in MCPyV virions. Moreover, alteration of the initiation codon of the VP3 ORF does not alter the infectivity of MCPyV in cell culture. These observations indicate that VP3 may be expressed under only certain conditions (92).

The study of MCPyV prevalence in the human population suggests that this virus is part the skin microbiota (38). Exposure to this agent occurs early in life, as demonstrated by serological surveys, which showed that 20% to 40% of children less than five years old test positive for antibodies against this virus. In addition, positivity increases to 80% in individuals more than 50 years old (27,50,93-97). Transmission may occur via direct contact with the skin or saliva (98). In addition, airborne as well as fecal-oral routes of transmission have been proposed (99-101). A prospective study conducted with bisexual and homosexual adults who were controlled at six month intervals showed that primary infection is asymptomatic in most of the cases. Analysis of clinical variables such as fever, presence of sprouts, diarrhea or loss of weight, as well as cytological tests involving the counting of erythrocytes and lymphocytes (including CD4 and CD8 populations) were unable to differentiate control individuals from those that had seroconverted (97). As described above, MCPyV is considered to be a part of the skin microbiota. However, detection of viral DNA is very frequent in patients with MCC, even at sites that are distant from the lesion (80,102). Viral DNA has been detected in blood, eyebrows, nasal swabs and aspirates, and adrenal glands (80,99,101-104). The presence of this virus has been analyzed in other tissues and was not detected in samples from the central nervous system (105). However, analysis of viral presence in lymphoid tissues led to inconclusive results (106-108).

Pathogenesis of Merkel cell polyomavirus. Merkel cells are located at the basal layer of the epithelia of the skin and oral mucosa and are in direct contact with the tactile neural discs, to which these cells transmit mechanical information. Merkel cells are associated with afferent demyelinated neurons of the dermis (109). In the skin, these cells are part of the somatic sensorial system and are classified as exteroceptors. However, in the epithelium of the mouth, the format and function of these cells increase in complexity (110). Although MCC is diagnosed by the detection of specific markers, namely, cytokeratin 20 and CD56, the origin of Merkel cells remains a matter of debate (111). Considering the analysis of the expression of different cellular markers, several hypotheses have been proposed, including epithelial stem cells and pre-pro-B lymphocytes being the precursors of Merkel cells (112-116). However, independent of the anatomic locations of these cells, when observed by electron microscopy, Merkel cell tumors exhibit neuroendocrine granules, suggesting the neuroendocrine origin of these malignancies (117). Results from a recent study suggest that dermal fibroblasts may be the primary cells infected by MCPyV (118). Interestingly, analysis of MCPyV expression and replication in dermal fibroblasts from different species demonstrated that only human and chimpanzee cells were permissive for the production of infectious MCPyV (119). However, no viral DNA or protein has been detected in the dermis adjacent to MCPyV-positive MCCs (120).

Immunosuppression is another important factor in MCC development and progression. In fact, immunocompromised individuals exhibit a higher (16-fold) relative risk for MCC than the normal population (70). Immunosuppression allows the establishment of persistent infections, even in the presence of immunogenic viral antigens (121). In addition, similar to other tumor viruses, including human papillomaviruses, Kaposi's sarcoma herpesvirus and human T lymphotropic



virus type-I, MCPyV exhibits a series of immune evasion mechanisms. For instance, it has been observed that the LT antigen inhibits the activity of the transcription factor C/EBP β , which downregulates the expression of Toll-like receptor 9 (122). This fact makes the cell unable to detect unmethylated double-stranded DNA in its cytoplasm (123). Moreover, the sT antigen binds NF- κ B (NEMO/IKK- γ), altering an important pathway involved in innate immunity (124). In addition, MCPyV-positive MCCs present lower levels of MHC I than MCPyV-negative tumors. Usually, cells lacking MHC I expression are eliminated by natural killers (NK) cells. Importantly, MCPyV reduces the expression of the NK-activating receptor group 2, member D (NKG2D), allowing the survival of tumor cells expressing low levels of MHC I (125). However, MHC I expression may be induced in MCPyV-positive cells in response to IFN- γ , which may prove relevant for MCC treatment (126).

Studies conducted in different populations have shown that patients diagnosed with MCC are at higher risk of developing second neoplasias (66,127-129). Among these neoplasias, malignant skin tumors are the most frequent, highlighting the effect of UV radiation in the genesis of these different types of tumors (127,130). In addition, lymphoid leukemia is also common in MCC patients (131). Importantly, in many cases, the second neoplasia is an independent primary MCC (132-138).

Finally, the presence of MCPyV has been analyzed in different human tumors. The results from several studies addressing this issue are summarized in Table 1.

John Cunningham polyomavirus

The human polyomavirus JCPyV is genetically related to BKPyV and SV40. The first report of this virus was made by Zurhein and Chou more than fifty years ago (139). Using electron microscopy, these authors observed the presence of particles similar to papovavirus in oligodendrocytes present in demyelinated areas of the brains of patients with PML (139). The virus was then isolated after the inoculation of brain extracts from a patient with PML (patient John Cunningham) in primary human fetal glial cells (33).

Different studies have shown that 40-60% of all adults exhibit IgG antibodies against the JCPyV VP1 protein (31,51). Initial subclinical infections occur during childhood, and the virus establishes lifelong infections in specific sites, such as the proximal kidney tubule. On rare occasions, the virus may be reactivated. This phenomenon is more frequent in immunosuppressed individuals, such as patients with AIDS or recipients of organ transplants, than in non-immunocompromised individuals (31). Viral reactivation may lead to the development of PML, a fatal demyelinating disorder of the central nervous system caused by the destruction of oligodendrocytes as a consequence of the lytic viral cycle (11,140). In addition, this virus has been associated with renal diseases in immunosuppressed individuals and organ transplant recipients (141-144).

Viral biology and epidemiology. The 5130-bp genome of JCPyV (J02226) presents the same general characteristics that are typical of PyVs, as described above (1) (Figure 2). This virus expresses three structural proteins, namely, VP1, VP2 and VP3, from its late region, with VP1 being the major capsid protein (145). In addition, this virus expresses three regulatory proteins. The LT and sT antigens are expressed from the early region, while the gene coding for agnoprotein

is located in the late region. Three splicing variants have been reported for the LT antigen, namely, T₁₃₅, T₁₃₆, and T₁₆₅, which are expressed in infected cells during the lytic cycle (146,147). In addition, JCPyV expresses a microRNA that may be involved in regulation of the LT antigen, as reported for MCPyV (5).

The JCPyV LT antigen shares structural and functional homology with LT antigens from other PyVs. Similar to LT antigens from other PyVs the JCPyV LT antigen and its splicing variants are multifunctional proteins that interact with viral and host DNA and proteins affecting their functions. As previously mentioned, LT antigens are important for the induction of DNA replication in infected cells, allowing the virus to usurp the DNA replication machinery to amplify its genome (10,11). This occurrence fosters viral multiplication in permissive cells and viral transmission. However, JCPyV infection of nonpermissive cells may lead to cellular transformation (57). Expression of the LT antigen may be regulated by the expression of a viral microRNA complementary to the 3' region of the early mRNA. In addition, this microRNA targets the cellular mRNA that expresses UL16-binding protein 3 (ULBP3) (6), probably leading to inhibition of the antiviral response of NK cells (148).

Other viral proteins are involved in the control of the cell cycle and viral replication. JCPyV also expresses an sT antigen. As described above for TSPyV and JCPyV, the sT antigen binds the phosphatase PP2A, promoting cell proliferation (149). In addition, sT targets members of the pRb family, further affecting cell cycle control (150). The JCPyV agnoprotein has been described as a multifunctional factor (151). Functional elimination of this protein by deletion or mutation leads to a dramatic downregulation of viral genome replication and transcription (22). However, the effect of this protein on host cell homeostasis is not clearly understood. The agnoprotein of JCPyV may bind several cellular factors, including p53, YB-1, Ku70, FEZ1, HP1 α , PP2A, AP-3, PCNA, and α -SNAP. In addition, this protein can bind LT, sT and VP1 and regulate the viral cycle (22,152). JCPyV variants carrying deletions in the gene coding for the agnoprotein have been linked to the development of severe encephalopathy, which is of clinical relevance (153).

JCPyV inoculation in animal models, including rodents and nonhuman primates, that are not permissive to the replication of this virus resulted in the formation of tumors. Since then, the tumorigenic potential of this virus in humans and the association of this virus with the development of some human malignancies has been a matter of debate (154) (Table 1). To date, no conclusive prospective studies supporting a causal association between JCPyV infection and cancer development in humans have been conducted. Several case-control studies, sometimes nested within cohort studies, have been conducted to establish the association between JCPyV seropositivity and specific human tumor types, including colorectal cancer (155-161), lymphoma (162,163), central nervous system tumors (164-166), esophageal carcinoma (167), carcinoma of the bladder (168), and prostate cancer (169). These results should be interpreted with caution since anti-JCPyV antibodies may persist for decades, indicating previous exposure to the agent but not viral reactivation. On the other hand, detection of JCPyV by qPCR in the urine indicates active replication and has been applied for the detection of the virus in cases of colorectal and bladder carcinomas (170,171).

To date, the oncogenic potential of this virus has not been clearly established. Moreover, although JCPyV DNA has been



detected in a varying percentage of gastrointestinal tumors, the IARC classifies this virus as a group 2B carcinogen, indicating that JCPV is possibly carcinogenic to humans (51,161).

It is well established that immunosuppressed individuals exhibit an increased risk of cancer. Few studies have addressed the prevalence of JCPyV in tumors of immunosuppressed patients. In a recent study, Bolting et al. observed a higher prevalence of JCPyV DNA in the normal mucosa of the gastrointestinal tracts of patients who received immunosuppressant therapy than in immunocompetent control individuals (23,7% vs. 6,3%; $p = 0,02$) (172). Importantly, organ transplant recipients exhibited a relative risk of 10.4 (prevalence 35,3%) for carrying viral DNA. Altogether, these results suggest that persistent viral infection in immunosuppressed individuals may be a risk factor for tumor development. Further studies are needed to confirm this hypothesis. Another study compared the prevalence of JCPyV between the normal colonic epithelium and adenomatous polyps from liver transplant recipients (LTRs) and normal and adenoma tissue samples from control patients (173). The authors observed that LTRs exhibited higher prevalence of JCPyV DNA in the normal colonic mucosa than the control patients (67% vs. 24%, $p = 0.025$). In addition, the JCPyV LT antigen protein was detected at a higher proportion in adenomas from LTRs than in those from immunocompetent patients (50% vs. 5%, $p < 0.001$) (173). These results suggest that JCPyV may be reactivated under immunosuppressive conditions.

Altogether, the data discussed above underscore the need for further molecular and epidemiological studies to gain insights into the mechanisms of JCPyV pathogenesis. Molecular studies conducted to better characterize the impact of viral proteins in cellular processes will be needed to determine the mechanisms of JCPyV-mediated cell transformation. In addition, epidemiological, prospective and multicentric studies will be necessary to determine the existence of causality between JCPyV and specific human cancers.

BK polyomavirus

Ninety percent of adults worldwide have been exposed to BKPyV. As is the case for the other PyVs discussed in this review, initial BKPyV infection occurs during childhood (174). The virus seems to be transmitted via multiple routes, including respiratory, urine-oral, feco-oral, and transplacental and via transplantation of infected organs (174-179).

Four BKPyV genotypes, namely, I, II, III and IV have been described based on variations in the nucleotide sequence of the gene coding the structural protein VP1 and constitute different serotypes (49,180) (Figure 2). BKPyV expresses two minor structural proteins, namely, VP2 and VP3, which participate in nuclear entry upon infection and virion mounting (181). In addition, BKPyV expresses a microRNA with similar functional characteristics as those described for JCPyV (5,6,148). Finally, the BKPyV late region expresses an agnoprotein important for the productive life cycle of the virus (182,183). Agnoprotein has been shown to interact with the N-ethylmaleimide-sensitive factor attachment protein alpha (α -SNAP), affecting the secretion of fusion reporter proteins and supporting a role for this viral protein in the regulation of exocytosis (184). In addition, agnoprotein also targets the proliferating cell nuclear antigen (PCNA), down-regulating DNA synthesis and cell proliferation *in vitro* (185). This observation suggests that agnoprotein may inhibit viral DNA synthesis at late stages of the viral cycle to allow virion

mounting. The early region of the BKPyV genome expresses LT and sT antigens. Recently, the expression of a truncated form of the T antigen (trT) has been reported (186).

After primary infection, the virus may establish persistent infection in uroepithelial cells, oligodendrocytes and mononuclear cells from the blood (49,174). In a great majority of the cases, the infection is asymptomatic, and the virus can be detected in the urine of 0,5% to 20% of the healthy population (178,187). However, BKPyV can be reactivated in organ transplant recipients due to the immunosuppressant therapy used in these patients. Viral reactivation is associated with increased viral load and destruction of infected tissues (49). In fact, BKPyV is one of the leading causes of kidney transplant failure, and the prevalence of this virus in kidney transplant recipients is high (10% to 60%). In addition, this virus is associated with ureteric stenosis and nephropathy (178,179). Viral reactivation has also been associated with old age, pregnancy, diabetes mellitus, congenic immunodeficiency and AIDS (179). Finally, BKPyV has also been detected in HIV-associated salivary gland disease (HIVSGD), suggesting that this virus may also exhibit tropism for this organ (188).

As observed for other PyVs, the complete BKPyV genome or fragments containing the early genes are able to transform several cell types from different animals in cell culture systems. However, transformation of human cells by BKPyV is inefficient (189). The LT antigen seems to be the main transformation-associated protein in BKPyV. This protein transforms rodent cells and immortalizes human cells in the presence of activated oncogenes such *ras* and *myc* (189,190). *In vitro* studies have shown that the LT antigen from BKPyV binds p53 as well as members of the pRb family (183).

BKPyV DNA has been detected in several human cancers, including carcinomas of the lung, pancreas, liver, urogenital tract, head and neck (191,192). In addition, this virus has been detected in rhabdomyosarcoma, Kaposi's sarcoma and brain tumors (192). The results from these and other studies are presented in Table 1. In addition, a recent study showed that patients with bladder cancer exhibit higher median antibody titers against this virus than matched controls. Moreover, it was observed that the risk of bladder cancer was significantly increased in individuals exhibiting high antibody titers against BKPyV and MCPyV (168).

As in the case of JCPyV, BKPyV is considered a possible human carcinogen (2B) by the IARC. Therefore, comprehensive prospective epidemiological studies are needed in order to prove or refute the role of BKPyV in human cancers.

Concluding remarks

The proven cell transforming ability of different members of the *Polyomaviridae* family has promoted to studies to determine the existence of an association between different HPyVs and cancer development. The first HPyVs were described more than 45 years ago. However, recent technological advances have led to the swift identification of several PyVs in human samples. Epidemiological and molecular data has established MCPyV as a *bona fide* tumor virus. Moreover, BKPyV and JCPyV are possibly involved in the etiology of specific human malignancies.

In fact, there is a possibility that other HPyVs may be related with different malignancies in humans. Multiple studies conducted during the last decade have addressed the presence of almost all the known HPyVs in human tumors (Table 1). For instance, TS lesions associated with TSPyV infection that affect individuals who receive immunosuppressing



therapies are characterized by the expansion of the inner root sheath epithelium, high expression of the proliferation marker Ki-67, presence of eosinophil granules and the trichohyalin protein in the hyperproliferative cells of the internal root of the hair bulb (193,194). Importantly, TSPyV sT antigen expression has been linked to the deregulation of cellular pathways involved in the control of cell proliferation and apoptosis (195). TSPyV sT and middle T (mT) antigens share the first 196 amino acids, and this region harbors a PP2A-binding motif (196). To date, the role of the mT antigen in the regulation of cell proliferation by TSPyV is unknown; however, the role has been well established for MuPyV (197,198). A recent study has shown that the TSPyV mT antigen interacts with PP2A via a Zn²⁺-binding domain motif and that this interaction is required for the activation of the pro-proliferative MEK/ERK/MNK1 signaling axis (199). As described above, the PP2A-MAPK-regulated pathway is critical for the control of apoptosis and cell proliferation. Therefore, dysregulation of this pathway may lead to uncontrolled cell growth (200,201).

HPyV6, as well as MCPyV, was detected in human skin health samples as part of the microbiome (38,202). Many studies have been conducted to analyze the existence of an association between HPyV6 and lesions of the skin (46,203,204) and other tissues (47,205). To date, these efforts have not led to conclusive results. Interestingly, a recent study detected HPyV6 DNA and the VP1 core protein in samples from patients with melanoma treated with BRAF inhibitors (206). However, and intriguingly, all the samples also tested positive for HPyV7 and HPV. Nonetheless, the HPyV6 DNA load detected suggests that this virus may contribute to epithelial cell proliferation in these patients. The HPyV6 sT antigen contains a PP2A binding domain that may be involved in the activation of MAPK signaling cascade and c-Jun (237).

Some HPyVs have been linked to specific severe pathologies, mainly in immunosuppressed individuals. The growing number of individuals infected with HIV or being treated with immunosuppressant drugs raises the concern that new conditions associated with known or yet-to-be-discovered HPyVs may arise. Therefore, further studies are needed to better characterize these agents and their biology, epidemiology and associations with malignancies in human populations.

ACKNOWLEDGMENTS

This research was supported by grants from FAPESP (2008/57889-1) and (CNPq 573799/2008-3).

AUTHOR CONTRIBUTIONS

Prado JC prepared the text describing the general characteristics of PyVs, details on Merkel cell PyVs and Table 1. Monezi TA prepared the text describing the general characteristics of TSPyV and its association with human pathologies. She also prepared the illustrations in Figures 1 and 2 and helped prepare Table 1. Amorim AT prepared the text describing the general characteristics of JCPyV and its association with human pathologies. Lino V prepared the text describing the general characteristics of BKPyV and its association with human pathologies. Paladino A revised the entire text and helped prepare Table 1. Boccardo E prepared, revised and corrected the entire text.

REFERENCES

1. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. *Clin Microbiol Rev.* 2012;25(3):471-506, <http://dx.doi.org/10.1128/CMR.05031-11>.
2. Imperiale MJ, Major EO. Polyomaviridae. In: Fields BN, Knipe DM, Howley PM. *Fields virology*. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 2263-2298.
3. Calvignac-Spencer S, Feltkamp MC, Daugherty MD, Moens U, Ramqvist T, John R, et al. A taxonomy update for the family Polyomaviridae. *Arch Virol.* 2016;161(6):1739-50, <http://dx.doi.org/10.1007/s00705-016-2794-y>.
4. Moens U, Calvignac-Spencer S, Lauber C, Ramqvist T, Feltkamp MC, Daugherty MD, et al. ICTV Virus Taxonomy Profile: Polyomaviridae. *J Gen Virol.* 2017;98(6):1159-60, <http://dx.doi.org/10.1099/jgv.0.000839>.
5. Lee S, Paulson KG, Murchison EP, Afanasiev OK, Alkan C, Leonard JH, et al. Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. *J Clin Virol.* 2011;52(3):272-5, <http://dx.doi.org/10.1016/j.jcv.2011.08.012>.
6. Bauman Y, Nachmani D, Vitenshtein A, Tsukerman P, Drayman N, Stern-Ginossar N, et al. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. *Cell Host Microbe.* 2011;9(2):93-102, <http://dx.doi.org/10.1016/j.chom.2011.01.008>.
7. Stewart SE, Eddy BE, Borgese N. Neoplasms in mice inoculated with a tumor agent carried in tissue culture. *J Natl Cancer Inst.* 1958;20(6):1223-43, <http://dx.doi.org/10.1093/jnci/20.6.1223>.
8. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. *J Natl Cancer Inst.* 1999; 91(2):119-34, <http://dx.doi.org/10.1093/jnci/91.2.119>.
9. Howes SH, Bockus BJ, Schaffhausen BS. Genetic analysis of polyomavirus large T nuclear localization: nuclear localization is required for productive association with pRb family members. *J Virol.* 1996;70(6): 3581-8.
10. Tyagarajan SK, Frisque RJ. Stability and function of JC virus large T antigen and T' proteins are altered by mutation of their phosphorylated threonine 125 residues. *J Virol.* 2006;80(5):2083-91, <http://dx.doi.org/10.1128/JVI.80.5.2083-2091.2006>.
11. Assetta B, Atwood WJ. The biology of JC polyomavirus. *Biol Chem.* 2017;398(8):839-55, <http://dx.doi.org/10.1515/hsz-2016-0345>.
12. Sawai ET, Butel JS. Association of a cellular heat shock protein with simian virus 40 large T antigen in transformed cells. *J Virol.* 1989;63(9): 3961-73.
13. Ali SH, DeCaprio JA. Cellular transformation by SV40 large T antigen: interaction with host proteins. *Semin Cancer Biol.* 2001;11(1):15-23, <http://dx.doi.org/10.1006/scbi.2000.0342>.
14. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. *PLoS Pathog.* 2010;6(7):e1001024, <http://dx.doi.org/10.1371/journal.ppat.1001024>.
15. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. *Mol Cell Biol.* 2002;22(7):2111-23, <http://dx.doi.org/10.1128/MCB.22.7.2111-2123.2002>.
16. Raghava S, Giorda KM, Romano FB, Heuck AP, Hebert DN. SV40 late protein VP4 forms toroidal pores to disrupt membranes for viral release. *Biochemistry.* 2013;52(22):3939-48, <http://dx.doi.org/10.1021/bi400036z>.
17. Giorda KM, Raghava S, Hebert DN. The Simian virus 40 late viral protein VP4 disrupts the nuclear envelope for viral release. *J Virol.* 2012;86(6):3180-92, <http://dx.doi.org/10.1128/JVI.07047-11>.
18. Raghava S, Giorda KM, Romano FB, Heuck AP, Hebert DN. The SV40 late protein VP4 is a viroporin that forms pores to disrupt membranes for viral release. *PLoS Pathog.* 2011;7(6):e1002116, <http://dx.doi.org/10.1371/journal.ppat.1002116>.
19. Daniels R, Sadowicz D, Hebert DN. A very late viral protein triggers the lytic release of SV40. *PLoS Pathog.* 2007;3(7):e98, <http://dx.doi.org/10.1371/journal.ppat.0030098>.
20. Henriksen S, Hansen T, Bruun JA, Rinaldo CH. The Presumed Polyomavirus Viroporin VP4 of Simian Virus 40 or Human BK Polyomavirus Is Not Required for Viral Progeny Release. *J Virol.* 2016;90(22):10398-413, <http://dx.doi.org/10.1128/JVI.01326-16>.
21. Okada Y, Endo S, Takahashi H, Sawa H, Umemura T, Nagashima K. Distribution and function of JCV agnoprotein. *J Neurovirol.* 2001;7(4): 302-6, <http://dx.doi.org/10.1080/13550280152537148>.
22. Saribas AS, Coric P, Hamazaspayan A, Davis W, Axman R, White MK, et al. Emerging From the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses. *J Cell Physiol.* 2016;231(10):2115-27, <http://dx.doi.org/10.1002/jcp.25329>.
23. Burkert O, Krefner S, Sinn L, Giese S, Simon C, Lilie H. Biophysical characterization of polyomavirus minor capsid proteins. *Biol Chem.* 2014;395(7-8):871-80.



24. Simon C, Klose T, Herbst S, Han BG, Sinz A, Glaeser RM, et al. Disulfide linkage and structure of highly stable yeast-derived virus-like particles of murine polyomavirus. *J Biol Chem.* 2014;289(15):10411-8, <http://dx.doi.org/10.1074/jbc.M113.484162>.
25. Ishizu KI, Watanabe H, Han SI, Kanesashi SN, Hoque M, Yajima H, et al. Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein. *J Virol.* 2001;75(1):61-72, <http://dx.doi.org/10.1128/JVI.75.1.61-72.2001>.
26. Deng YN, Zeng JY, Su H, Qu QM. Recombinant VLP-Z of JC Polyomavirus: A Novel Vector for Targeting Gene Delivery. *Intervirology.* 2015;58(6):363-8, <http://dx.doi.org/10.1159/000443832>.
27. Touzé A, Gaitan J, Arnold F, Cazal R, Fleury MJ, Combélas N, et al. Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies. *J Clin Microbiol.* 2010;48(5):1767-70, <http://dx.doi.org/10.1128/JCM.01691-09>.
28. Moriyama T, Marquez JP, Wakatsuki T, Sorokin A. Caveolar endocytosis is critical for BK virus infection of human renal proximal tubular epithelial cells. *J Virol.* 2007;81(16):8552-62, <http://dx.doi.org/10.1128/JVI.00924-07>.
29. Zhao L, Marciano AT, Rivet CR, Imperiale MJ. Caveolin- and clathrin-independent entry of BKPyV into primary human proximal tubule epithelial cells. *Virology.* 2016;492:66-72, <http://dx.doi.org/10.1016/j.virol.2016.02.007>.
30. Wollebo HS, Bellizzi A, Cossari DH, Salkind J, Safak M, White MK. The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC. *J Neurovirol.* 2016;22(5):615-25, <http://dx.doi.org/10.1007/s13365-016-0435-6>.
31. DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. *Nat Rev Microbiol.* 2013;11(4):264-76, <http://dx.doi.org/10.1038/nrmicro2992>.
32. Kaplan DR, Pallas DC, Morgan W, Schaffhausen B, Roberts TM. Mechanisms of transformation by polyoma virus middle T antigen. *Biochim Biophys Acta.* 1989;948(3):345-64.
33. Padgett BL, Walker DL, Zurhain GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. *Lancet.* 1971;1(7712):1257-60, [http://dx.doi.org/10.1016/S0140-6736\(71\)91777-6](http://dx.doi.org/10.1016/S0140-6736(71)91777-6).
34. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. *Lancet.* 1971;1(7712):1253-7, [http://dx.doi.org/10.1016/S0140-6736\(71\)91776-4](http://dx.doi.org/10.1016/S0140-6736(71)91776-4).
35. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, et al. Identification of a third human polyomavirus. *J Virol.* 2007;81(8):4130-6, <http://dx.doi.org/10.1128/JVI.00028-07>.
36. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. *PLoS Pathog.* 2007;3(5):e64, <http://dx.doi.org/10.1371/journal.ppat.0030064>.
37. Feng H, Shuda M, Chang Y, Moore PS. Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma. *Science.* 2008;319(5866):1096-100, <http://dx.doi.org/10.1126/science.1152586>.
38. Schowalter RM, Pastrana D V, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. *Cell Host Microbe.* 2010;7(6):509-15, <http://dx.doi.org/10.1016/j.chom.2010.05.006>.
39. Scuda N, Hofmann J, Calvignac-Spencer S, Ruprecht K, Liman P, Kuhn J, et al. A Novel Human Polyomavirus Closely Related to the African Green Monkey-Derived Lymphotropic Polyomavirus. *J Virol.* 2011;85(9):4586-90, <http://dx.doi.org/10.1128/JVI.02602-10>.
40. Siebrasse EA, Reyes A, Lim ES, Zhao G, Mkakosya RS, Manary MJ, et al. Identification of MW Polyomavirus, a novel polyomavirus in human stool. *J Virol.* 2012;86(19):10321-6, <http://dx.doi.org/10.1128/JVI.01210-12>.
41. Lim ES, Reyes A, Antonio M, Saha D, Ikumapayi UN, Adeyemi M, et al. Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant origin that encodes a unique T antigen by alternative splicing. *Virology.* 2013;436(2):295-303, <http://dx.doi.org/10.1016/j.virol.2012.12.005>.
42. Korup S, Rietscher J, Calvignac-Spencer S, Trusch F, Hofmann J, Moens U, et al. Identification of a Novel Human Polyomavirus in Organs of the Gastrointestinal Tract. *PLoS One.* 2013;8(3):1-7, <http://dx.doi.org/10.1371/journal.pone.0058021>.
43. Mishra N, Pereira M, Rhodes RH, An P, Pipas JM, Jain K, et al. Identification of a novel Polyomavirus in a pancreatic transplant recipient with retinal blindness and Vasculitic Myopathy. *J Infect Dis.* 2014;210(10):1595-9, <http://dx.doi.org/10.1093/infdis/jiu250>.
44. Gheit T, Dutta S, Oliver J, Robitaille A, Hampras S, Combes JD, et al. Isolation and characterization of a novel putative human polyomavirus. *Virology.* 2017;506:45-54, <http://dx.doi.org/10.1016/j.virol.2017.03.007>.
45. Delbue S, Comar M, Ferrante P. Review on the relationship between human polyomaviruses-associated tumors and host immune system. *Clin Dev Immunol.* 2012;2012:542092, <http://dx.doi.org/10.1155/2012/542092>.
46. Scola N, Wieland U, Silling S, Altmeyer P, Stücker M, Kreuter A. Prevalence of human polyomaviruses in common and rare types of non-Merkel cell carcinoma skin cancer. *Br J Dermatol.* 2012;167(6):1315-20, <http://dx.doi.org/10.1111/j.1365-2133.2012.11141.x>.
47. Saláková M, Košlabová E, Vojtchová Z, Tachezy R, Šroller V. Detection of human polyomaviruses MCPyV, HPyV6, and HPyV7 in malignant and non-malignant tonsillar tissues. *J Med Virol.* 2016;88(4):695-702, <http://dx.doi.org/10.1002/jmv.24385>.
48. Kazem S, van der Meijden E, Kooijman S, Rosenberg AS, Hughey LC, Browning JC, et al. Trichodysplasia spinulosa is characterized by active polyomavirus infection. *J Clin Virol.* 2012;53(3):225-30, <http://dx.doi.org/10.1016/j.jcv.2011.11.007>.
49. Jiang M, Abend JR, Johnson SF, Imperiale MJ. The role of polyomaviruses in human disease. *Virology.* 2009;384(2):266-73, <http://dx.doi.org/10.1016/j.virol.2008.09.027>.
50. Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, et al. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. *Clin Vaccine Immunol.* 2011;18(10):1737-43, <http://dx.doi.org/10.1128/CVI.05175-11>.
51. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Malaria and some polyomaviruses (SV40, BK, JC, and Merkel Cell Viruses). *IARC Monogr Eval Carcinog Risks Hum.* 2014;104:9-350.
52. Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. *Cancer Res.* 2008;68(13):5009-13, <http://dx.doi.org/10.1158/0008-5472.CAN-08-0949>.
53. Kenan DJ, Mieczkowski PA, Burger-Calderon R, Singh HK, Nickleit V. The oncogenic potential of BK-polyomavirus is linked to viral integration into the human genome. *J Pathol.* 2015;237(3):379-89, <http://dx.doi.org/10.1002/path.4584>.
54. Toptan T, Yousem SA, Ho J, Matsushima Y, Stabile LP, Fernández-Figueroas MT, et al. Survey for human polyomaviruses in cancer. *JCI Insight.* 2016;1(2):e85562, <http://dx.doi.org/10.1172/jci.insight.85562>.
55. Wendler P, Ciniawsky S, Kock M, Kube S. Structure and function of the AAA+ nucleotide binding pocket. *Biochim Biophys Acta.* 2012;1823(1):2-14, <http://dx.doi.org/10.1016/j.bbamcr.2011.06.014>.
56. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, et al. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. *Nature.* 2012;487(7408):491-5, <http://dx.doi.org/10.1038/nature11288>.
57. Delbue S, Comar M, Ferrante P. Review on the role of the human Polyomavirus JC in the development of tumors. *Infect Agent Cancer.* 2017;12:10, <http://dx.doi.org/10.1186/s13027-017-0122-0>.
58. Flaegstad T, Andresen PA, Johnsen JL, Asomani SK, Jørgensen GE, Vignarajasa S, et al. A possible contributory role of BK virus infection in neuroblastoma development. *Cancer Res.* 1999;59(5):1160-3.
59. Das D, Shah RB, Imperiale MJ. Detection and expression of human BK virus sequences in neoplastic prostate tissues. *Oncogene.* 2004;23(42):7031-46, <http://dx.doi.org/10.1038/sj.onc.1207920>.
60. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. *Cell.* 1990;60(1):167-76, [http://dx.doi.org/10.1016/0092-8674\(90\)90726-U](http://dx.doi.org/10.1016/0092-8674(90)90726-U).
61. Tung HY, Alemany S, Cohen P. The protein phosphatases involved in cellular regulation. 2. Purification, subunit structure and properties of protein phosphatases-2A0, 2A1, and 2A2 from rabbit skeletal muscle. *Eur J Biochem.* 1985;148(2):253-63, <http://dx.doi.org/10.1111/j.1432-1033.1985.tb08833.x>.
62. Alberts AS, Thorburn AM, Shenolikar S, Mummy MC, Feramisco JR. Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases. *Proc Natl Acad Sci U S A.* 1993;90(2):388-92, <http://dx.doi.org/10.1073/pnas.90.2.388>.
63. Glenn GM, Eckhart W. Mutation of a cysteine residue in polyomavirus middle T antigen abolishes interactions with protein phosphatase 2A, pp60c-src, and phosphatidylinositol-3 kinase, activation of c-fos expression, and cellular transformation. *J Virol.* 1993;67(4):1945-52.
64. Ronne H, Carlberg M, Hu GZ, Nehlin JO. Protein phosphatase 2A in *Saccharomyces cerevisiae*: effects on cell growth and bud morphogenesis. *Mol Cell Biol.* 1991;11(10):4876-84, <http://dx.doi.org/10.1128/MCB.11.10.4876>.
65. Schönthal AH. Role of serine/threonine protein phosphatase 2A in cancer. *Cancer Lett.* 2001;170(1):1-13, [http://dx.doi.org/10.1016/S0304-3835\(01\)00561-4](http://dx.doi.org/10.1016/S0304-3835(01)00561-4).
66. Toker C. Trabecular carcinoma of the skin. *Arch Dermatol.* 1972;105(1):107-10, <http://dx.doi.org/10.1001/archderm.1972.01620040075020>.
67. Reichgelt BA, Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. *Eur J Cancer.* 2011;47(4):579-85, <http://dx.doi.org/10.1016/j.jejca.2010.11.002>.
68. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. *J Am Acad Dermatol.* 2003;49(5):832-41, [http://dx.doi.org/10.1016/S0190-9622\(03\)02108-X](http://dx.doi.org/10.1016/S0190-9622(03)02108-X).
69. Youlten DR, Youl PH, Peter Soyer H, Fritschl L, Baade PD. Multiple primary cancers associated with Merkel cell carcinoma in Queensland,



- Australia, 1982-2011. *J Invest Dermatol.* 2014;134(12):2883-9, <http://dx.doi.org/10.1038/jid.2014.266>.
70. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. *J Am Acad Dermatol.* 2010;63(5):751-61, <http://dx.doi.org/10.1016/j.jaad.2010.02.056>.
 71. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. *J Am Acad Dermatol.* 2008;58(3):375-81, <http://dx.doi.org/10.1016/j.jaad.2007.11.020>.
 72. Duprat JP, Landman G, Salvajoli JV, Brechtbühl ER. A review of the epidemiology and treatment of Merkel cell carcinoma. *Clinics (Sao Paulo).* 2011;66(10):1817-23.
 73. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. *J Cutan Pathol.* 2010;37(1):20-7, <http://dx.doi.org/10.1111/j.1600-0560.2009.01370.x>.
 74. Campillo R, Gil-Carcedo E, Alonso D, Vallejo LA, Oñate JM, Gil-Carcedo LM. Primary cutaneous neuroendocrine carcinoma, Merkel cell carcinoma. Case series 1991-2012. *Acta Otorrinolaringol Esp.* 2013;64(6):396-402, <http://dx.doi.org/10.1016/j.otorri.2013.06.003>.
 75. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS. Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. *Am J Dermatopathol.* 2006;28(2):99-104, <http://dx.doi.org/10.1097/01.dad.0000183701.67366.c7>.
 76. Feng H, Kwun HJ, Liu X, Gjoerup O, Stolz DB, Chang Y, et al. Cellular and viral factors regulating Merkel cell polyomavirus replication. *PLoS One.* 2011;6(7):e22468, <http://dx.doi.org/10.1371/journal.pone.0022468>.
 77. Carter JJ, Daugherty MD, Qi X, Bheda-Malge A, Wipf GC, Robinson K, et al. Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes. *Proc Natl Acad Sci U S A.* 2013;110(31):12744-9, <http://dx.doi.org/10.1073/pnas.1303526110>.
 78. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. *J Virol.* 2010;84(14):7064-72, <http://dx.doi.org/10.1128/JVI.02400-09>.
 79. Martel-Jantin C, Filippone C, Cassar O, Peter M, Tomasic G, Vielh P, et al. Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. *Virology.* 2012;426(2):134-42, <http://dx.doi.org/10.1016/j.virol.2012.01.018>.
 80. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. *Proc Natl Acad Sci U S A.* 2008;105(42):16272-7, <http://dx.doi.org/10.1073/pnas.0806526105>.
 81. Foulongne V, Dereure O, Kluger N, Molès JP, Guillot B, Segondy M. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. *Br J Dermatol.* 2010;162(1):59-63, <http://dx.doi.org/10.1111/j.1365-2133.2009.09381.x>.
 82. Samimi M, Gardair C, Nicol JT, Arnold F, Touzé A, Coursaget P. Merkel cell polyomavirus in merkel cell carcinoma: clinical and therapeutic perspectives. *Semin Oncol.* 2015;42(2):347-58, <http://dx.doi.org/10.1053/j.seminoncol.2014.12.021>.
 83. Kwun HJ, Guastafierro A, Shuda M, Meinke G, Bohm A, Moore PS, et al. The minimum replication origin of merkel cell polyomavirus has a unique large T-antigen loading architecture and requires small T-antigen expression for optimal replication. *J Virol.* 2009;83(23):12118-28, <http://dx.doi.org/10.1128/JVI.01336-09>.
 84. Kwun HJ, Shuda M, Feng H, Camacho CJ, Moore PS, Chang Y. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. *Cell Host Microbe.* 2013;14(2):125-35, <http://dx.doi.org/10.1016/j.chom.2013.06.008>.
 85. Kwun HJ, Wendzicki JA, Shuda Y, Moore PS, Chang Y. Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting. *Oncogene.* 2017;36(49):6784-92, <http://dx.doi.org/10.1038/onc.2017.277>.
 86. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. *J Clin Invest.* 2011;121(9):3623-34, <http://dx.doi.org/10.1172/JCI46323>.
 87. Verhaegen ME, Mangelberger D, Harms PW, Eberl M, Wilbert DM, Meireles J, et al. Merkel Cell Polyomavirus Small T Antigen Initiates Merkel Cell Carcinoma-like Tumor Development in Mice. *Cancer Res.* 2017;77(12):3151-7, <http://dx.doi.org/10.1158/0008-5472.CAN-17-0035>.
 88. Borchert S, Czech-Sioli M, Neumann F, Schmidt C, Wimmer P, Dobner T, et al. High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened Merkel cell polyomavirus large T antigens. *J Virol.* 2014;88(6):3144-60, <http://dx.doi.org/10.1128/JVI.02916-13>.
 89. Stakaitytė G, Nwogu N, Dobson SJ, Knight LM, Wasson CW, Salguero FJ, et al. Merkel Cell Polyomavirus Small T Antigen Drives Cell Motility via Rho-GTPase-Induced Filopodium Formation. *J Virol.* 2018;92(2):e00940-17.
 90. Cheng J, Park DE, Berrios C, White EA, Arora R, Yoon R, et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. *PLoS Pathog.* 2017;13(10):e1006668, <http://dx.doi.org/10.1371/journal.ppat.1006668>.
 91. Hesbacher S, Pfitzer L, Wiedorfer K, Angermeyer S, Borst A, Haferkamp S, et al. RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells. *Oncotarget.* 2016;7(22):32956-68, <http://dx.doi.org/10.18632/oncotarget.8793>.
 92. Schowalter RM, Buck CB. The Merkel cell polyomavirus minor capsid protein. *PLoS Pathog.* 2013;9(8):e1003558, <http://dx.doi.org/10.1371/journal.ppat.1003558>.
 93. Carter JJ, Paulson KG, Wipf GC, Miranda D, Madeleine MM, Johnson LG, et al. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. *J Natl Cancer Inst.* 2009;101(21):1510-22, <http://dx.doi.org/10.1093/jnci/djp332>.
 94. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. *PLoS Pathog.* 2009;5(3):e1000363, <http://dx.doi.org/10.1371/journal.ppat.1000363>.
 95. Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. *PLoS Pathog.* 2012;8(4):e1002650, <http://dx.doi.org/10.1371/journal.ppat.1002650>.
 96. Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, et al. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. *Int J Cancer.* 2009;125(6):1250-6, <http://dx.doi.org/10.1002/ijc.24509>.
 97. Tolstov YL, Knauer A, Chen JG, Kensler TW, Kingsley LA, Moore PS, et al. Asymptomatic primary Merkel cell polyomavirus infection among adults. *Emerg Infect Dis.* 2011;17(8):1371-80, <http://dx.doi.org/10.3201/eid1708.110079>.
 98. Martel-Jantin C, Pedergrana V, Nicol JT, Leblond V, Tréguët DA, Tortevoye P, et al. Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings. *J Clin Virol.* 2013;58(1):288-91, <http://dx.doi.org/10.1016/j.jcv.2013.06.004>.
 99. Kantola K, Sadeghi M, Lahtinen A, Koskenvuo M, Aaltonen LM, Mäkitönen M, et al. Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and upper respiratory tract samples: implications for respiratory transmission and latency. *J Clin Virol.* 2009;45(4):292-5, <http://dx.doi.org/10.1016/j.jcv.2009.04.008>.
 100. Fratini M, Di Bonito P, La Rosa G. Oncogenic Papillomavirus and Polyomavirus in Water Environments: Is There a Potential for Waterborne Transmission? *Food Environ Virol.* 2014;6(1):1-12, <http://dx.doi.org/10.1007/s12560-013-9134-0>.
 101. Goh S, Lindau C, Tiveljung-Lindell A, Allander T. Merkel cell polyomavirus in respiratory tract secretions. *Emerg Infect Dis.* 2009;15(3):489-91, <http://dx.doi.org/10.3201/eid1503.081206>.
 102. Laude HC, Jonchère B, Maubec E, Carlotti A, Marinho E, Coutraud B, et al. Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. *PLoS Pathog.* 2010;6(8):e1001076, <http://dx.doi.org/10.1371/journal.ppat.1001076>.
 103. Matsushita M, Kuwamoto S, Iwasaki T, Higaki-Mori H, Yashima S, Kato M, et al. Detection of Merkel cell polyomavirus in the human tissues from 41 Japanese autopsy cases using polymerase chain reaction. *Intervirology.* 2013;56(1):1-5, <http://dx.doi.org/10.1159/000338620>.
 104. Hampras SS, Michel A, Schmitt M, Waterboer T, Kranz L, Gheyt T, et al. Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma. *Infect Agent Cancer.* 2015;10:35, <http://dx.doi.org/10.1186/s13027-015-0030-0>.
 105. Focosi D, Maggi F, Andreoli E, Lanini L, Ceccherini-Nelli L, Petrini M. Polyomaviruses other than JCV are not detected in progressive multifocal leukoencephalopathy. *J Clin Virol.* 2009;45(2):161-2, <http://dx.doi.org/10.1016/j.jcv.2009.04.009>.
 106. Pantulu ND, Pallasch CP, Kurz AK, Kassem A, Frenzel L, Sodenkamp S, et al. Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells. *Blood.* 2010;116(24):5280-4, <http://dx.doi.org/10.1182/blood-2010-02-269829>.
 107. Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras MT, et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. *Int J Cancer.* 2009;125(6):1243-9, <http://dx.doi.org/10.1002/ijc.24510>.
 108. Toracchio S, Foyle A, Sroller V, Reed JA, Wu J, Kozinetz CA, et al. Lymphotropism of Merkel cell polyomavirus infection, Nova Scotia, Canada. *Emerg Infect Dis.* 2010;16(11):1702-9, <http://dx.doi.org/10.3201/eid1611.100628>.
 109. Alam M, Bordeaux JS, Yu SS, editors. *Merkel Cell Carcinoma* [Internet]. New York: Springer; 2013. Available from: <http://link.springer.com/10.1007/978-1-4614-6608-6>



110. Iggo A, Muir AR. The structure and function of a slowly adapting touch corpuscle in hairy skin. *J Physiol.* 1969;200(3):763-96, <http://dx.doi.org/10.1113/jphysiol.1969.sp008721>.
111. Gallego R, García-Caballero T, Fraga M, Beiras A, Forteza J. Neural cell adhesion molecule immunoreactivity in Merkel cells and Merkel cell tumours. *Virchows Arch.* 1995;426(3):317-21, <http://dx.doi.org/10.1007/BF00191370>.
112. Tilling T, Moll I. Which are the cells of origin in merkel cell carcinoma? *J Skin Cancer.* 2012;2012:680410, <http://dx.doi.org/10.1155/2012/680410>.
113. Moll I, Paus R, Moll R. Merkel cells in mouse skin: intermediate filament pattern, localization, and hair cycle-dependent density. *J Invest Dermatol.* 1996;106(2):281-6, <http://dx.doi.org/10.1111/1523-1747.ep12340714>.
114. Visvader JE, Stingl J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. *Genes Dev.* 2014;28(11):1143-58, <http://dx.doi.org/10.1101/gad.242511.114>.
115. Lemasson G, Coquart N, Lebonvallet N, Boulais N, Galibert MD, Marcocelles P, et al. Presence of putative stem cells in Merkel cell carcinomas. *J Eur Acad Dermatol Venereol.* 2012;26(6):789-95, <http://dx.doi.org/10.1111/j.1468-3083.2011.04132.x>.
116. Zur Hausen A, Rennspiess D, Winnepenninckx V, Speel EJ, Kurz AK. Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. *Cancer Res.* 2013;73(16):4982-7, <http://dx.doi.org/10.1158/0008-5472.CAN-13-0616>.
117. Tang CK, Toker C. Trabecular carcinoma of the skin: an ultrastructural study. *Cancer.* 1978;42(5):2311-21, [http://dx.doi.org/10.1002/1097-0142\(197811\)42:5<2311::AID-CNCR2820420531>3.0.CO;2-L](http://dx.doi.org/10.1002/1097-0142(197811)42:5<2311::AID-CNCR2820420531>3.0.CO;2-L).
118. Liu X, Hein J, Richardson SC, Basse PH, Toptan T, Moore PS, et al. Merkel cell polyomavirus large T antigen disrupts lysosome clustering by translocating human Vamp6p from the cytoplasm to the nucleus. *J Biol Chem.* 2011;286(19):17079-90, <http://dx.doi.org/10.1074/jbc.M110.192856>.
119. Liu W, Krump NA, MacDonald M, You J. Merkel Cell Polyomavirus Infection of Animal Dermal Fibroblasts. *J Virol.* 2018;92(4):e01610-17.
120. Sauer CM, Haugg AM, Chteinberg E, Rennspiess D, Winnepenninckx V, Speel EJ, et al. Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma. *Crit Rev Oncol Hematol.* 2017;116:99-105, <http://dx.doi.org/10.1016/j.critrevonc.2017.05.009>.
121. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. *Cancer Immunol Res.* 2014;2(1):27-36, <http://dx.doi.org/10.1158/2326-6066.CIR-13-0087>.
122. Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, et al. The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. *J Virol.* 2013;87(23):13009-19, <http://dx.doi.org/10.1128/JVI.01786-13>.
123. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. *Nature.* 2004;430(6996):257-63, <http://dx.doi.org/10.1038/nature02761>.
124. Griffiths DA, Abdul-Sada H, Knight LM, Jackson BR, Richards K, Prescott EL, et al. Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. *J Virol.* 2013;87(24):13853-67, <http://dx.doi.org/10.1128/JVI.02159-13>.
125. Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, et al. Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. *Front Immunol.* 2014;5:122, <http://dx.doi.org/10.3389/fimmu.2014.00122>.
126. Paulson KG, Park SY, Vandevan NA, Lachance K, Thomas H, Chapuis AG, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. *J Am Acad Dermatol.* 2018;78(3):457-63.e2, <http://dx.doi.org/10.1016/j.jaad.2017.10.028>.
127. Bzhalava D, Bray F, Storm H, Dillner J. Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. *Br J Cancer.* 2011;104(1):178-80, <http://dx.doi.org/10.1038/sj.bjc.6605989>.
128. Koljonen V, Kukko H, Tukiainen E, Böbling T, Sankila R, Joensuu H, et al. Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. *Cancer Epidemiol.* 2010;34(1):62-5, <http://dx.doi.org/10.1016/j.canep.2009.12.007>.
129. Howard RA, Dores GM, Curtis RE, Anderson WF, Travis LB. Merkel cell carcinoma and multiple primary cancers. *Cancer Epidemiol Biomarkers Prev.* 2006;15(8):1545-9, <http://dx.doi.org/10.1158/1055-9965.EPI-05-0895>.
130. Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. *Cancer Epidemiol Biomarkers Prev.* 1999;8(2):153-8.
131. Kaae J, Hansen AV, Biggar RJ, Boyd HA, Moore PS, Wohlfahrt J, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. *J Natl Cancer Inst.* 2010;102(11):793-801, <http://dx.doi.org/10.1093/jnci/djq120>.
132. Satter EK, Derienzo DP. Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp. *J Cutan Pathol.* 2008;35(7):685-91, <http://dx.doi.org/10.1111/j.1600-0560.2007.00874.x>.
133. Harms PW. Update on Merkel Cell Carcinoma. *Clin Lab Med.* 2017;37(3):485-501, <http://dx.doi.org/10.1016/j.cll.2017.05.004>.
134. Thakur S, Chaliouli K, Hayes M, While A. Bilateral primary Merkel cell carcinoma of the upper lid misdiagnosed as Basal cell carcinoma. *Orbit.* 2008;27(2):139-41, <http://dx.doi.org/10.1080/01676830701556715>.
135. Schrama D, Thiemann A, Houben R, Kähler KC, Becker JC, Hauschild A. Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis. *Arch Dermatol.* 2010;146(6):687-9, <http://dx.doi.org/10.1001/archdermatol.2010.121>.
136. Ahronowitz IZ, Daud AI, Leong SP, Shue EH, Bastian BC, McCalmont TH, et al. An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. *J Cutan Pathol.* 2011;38(10):801-7.
137. Pollock J, Caranosos T, Polack EP. Metachronous merkel cell carcinoma: a case report. *Case Rep Dermatol.* 2011;3(3):206-8, <http://dx.doi.org/10.1159/000333008>.
138. Kamiyama T, Ohshima N, Satoh H, Fukumoto H, Katano H, Imakado S. Metachronous Merkel cell carcinoma on both cheeks. *Acta Derm Venereol.* 2012;92(1):54-6, <http://dx.doi.org/10.2340/00015555-1185>.
139. Zurhein G, Chou SM. Particles Resembling Papova Viruses in Human Cerebral Demyelinating Disease. *Science.* 1965;148(3676):1477-9, <http://dx.doi.org/10.1126/science.148.3676.1477>.
140. Reiss K, Khalili K. Viruses and cancer: lessons from the human polyomavirus, JCV. *Oncogene.* 2003;22(42):6517-23, <http://dx.doi.org/10.1038/sj.onc.1206959>.
141. Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M; Progressive Multifocal Leukoencephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. *Ther Adv Neurol Disord.* 2015;8(6):255-73, <http://dx.doi.org/10.1177/1756285615020282>.
142. Kawakami T, Sakai K, Kimura Y, Senoo Y, Hirabayashi Y, Nakazawa H, et al. Development of primary central nervous system lymphoma associated with human immunodeficiency virus and JC virus infection. *J Clin Exp Hematop.* 2014;54(3):211-7, <http://dx.doi.org/10.3960/journal.54.211>.
143. Thomas LD, Milstone AP, Vilchez RA, Zanwar P, Butel JS, Dummer JS. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. *Transplantation.* 2009;88(3):360-6, <http://dx.doi.org/10.1097/TP.0b013e3181ae5ff9>.
144. Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. *Transplantation.* 2007;84(3):323-30, <http://dx.doi.org/10.1097/01.tp.0000269706.59977.a5>.
145. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. *J Virol.* 1984;51(2):458-69.
146. Trowbridge PW, Frisque RJ. Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. *J Neuroviro.* 1995;1(2):195-206, <http://dx.doi.org/10.3109/1355289509113966>.
147. Del Valle L, White MK, Khalili K. Potential mechanisms of the human polyomavirus JC in neural oncogenesis. *J Neuropathol Exp Neurol.* 2008;67(8):729-40, <http://dx.doi.org/10.1097/JNEP.0b013e3181806631>.
148. Broekema NM, Imperiale MJ. miRNA regulation of BK polyomavirus replication during early infection. *Proc Natl Acad Sci U S A.* 2013;110(20):8200-5, <http://dx.doi.org/10.1073/pnas.1301907110>.
149. Sariyer IK, Khalili K, Safak M. Dephosphorylation of JC virus agnoproprotein by protein phosphatase 2A: inhibition by small t antigen. *Virology.* 2008;375(8):464-79, <http://dx.doi.org/10.1016/j.virol.2008.02.020>.
150. Bollag B, Hofstetter CA, Reviriego-Mendoza MM, Frisque RJ. JC virus small T antigen binds phosphatase PP2A and Rb family proteins and is required for efficient viral DNA replication activity. *PLoS One.* 2010;5(5):e10606, <http://dx.doi.org/10.1371/journal.pone.0010606>.
151. Khalili K, White MK, Sawa H, Nagashima K, Safak M. The agnoproprotein of polyomaviruses: a multifunctional auxiliary protein. *J Cell Physiol.* 2005;204(1):1-7, <http://dx.doi.org/10.1002/jcp.20266>.
152. Darbinyan A, Darbinian N, Safak M, Radhakrishnan S, Giordano A, Khalili K. Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. *Oncogene.* 2002;21(36):5574-81, <http://dx.doi.org/10.1038/sj.onc.1205744>.
153. Dang X, Wüthrich C, Gordon J, Sawa H, Koralnik IJ. JC virus encephalopathy is associated with a novel agnoproprotein-deletion JCV variant. *PLoS One.* 2012;7(4):e35793, <http://dx.doi.org/10.1371/journal.pone.0035793>.
154. Maginnis MS, Atwood WJ. JC virus: an oncogenic virus in animals and humans? *Semin Cancer Biol.* 2009;19(4):261-9, <http://dx.doi.org/10.1016/j.semcancer.2009.02.013>.
155. Casini B, Borgese L, Del Nonno F, Galati G, Izzo L, Caputo M, et al. Presence and incidence of DNA sequences of human polyomaviruses BKV and JCV in colorectal tumor tissues. *Anticancer Res.* 2005;25(2A):1079-85.
156. Coelho TR, Gaspar R, Figueiredo P, Mendonça C, Lazo PA, Almeida L. Human JC polyomavirus in normal colorectal mucosa, hyperplastic polyps, sporadic adenomas, and adenocarcinomas in Portugal. *J Med Virol.* 2013;85(12):2119-27, <http://dx.doi.org/10.1002/jmv.23705>.
157. Samaka RM, Abd El-Wahed MM, Aiad HA, Kandil MA, Al-Sharaky DR. Does JC virus have a role in the etiology and prognosis of Egyptian



- colorectal carcinoma? *APMIS*. 2013;121(4):316-28, <http://dx.doi.org/10.1111/apm.12001>.
158. Mou X, Chen L, Liu F, Lin J, Diao P, Wang H, et al. Prevalence of JC virus in Chinese patients with colorectal cancer. *PLoS One*. 2012;7(5):e35900, <http://dx.doi.org/10.1371/journal.pone.0035900>.
 159. Ksaa F, Allous A, Ziadi S, Mokni M, Trimeche M. Assessment and biological significance of JC polyomavirus in colorectal cancer in Tunisia. *J BUON*. 2015;20(3):762-9.
 160. Butcher LD, Garcia M, Arnold M, Ueno H, Goel A, Boland CR. Immune response to JC virus T antigen in patients with and without colorectal neoplasia. *Gut Microbes*. 2014;5(4):468-75, <http://dx.doi.org/10.4161/gmic.29573>.
 161. Vilkin A, Ronen Z, Levi Z, Morgenstern S, Halpern M, Niv Y. Presence of JC virus DNA in the tumor tissue and normal mucosa of patients with sporadic colorectal cancer (CRC) or with positive family history and Bethesda criteria. *Dig Dis Sci*. 2012;57(1):79-84, <http://dx.doi.org/10.1007/s10620-011-1855-z>.
 162. Tseng CE, Yeh CM, Fang CY, Shay J, Chen PL, Lin MC, et al. Detection of human JCPyV and BKPyV in diffuse large B-cell lymphoma of the GI tract. *Eur J Clin Microbiol Infect Dis*. 2014;33(4):665-72, <http://dx.doi.org/10.1007/s10096-013-2010-x>.
 163. Rollison DE, Engels EA, Halsey NA, Shah KV, Viscidi RP, Helzlsouer KJ. Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev*. 2006;15(3):543-50, <http://dx.doi.org/10.1158/1055-9965.EPI-05-0728>.
 164. Rollison DE, Helzlsouer KJ, Alberg AJ, Hoffman S, Hou J, Daniel R, et al. Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. *Cancer Epidemiol Biomarkers Prev*. 2003;12(5):460-3.
 165. Stolt A, Kjellin M, Sasnauskas K, Luostarinen T, Koskela P, Lehtinen M, et al. Maternal human polyomavirus infection and risk of neuroblastoma in the child. *Int J Cancer*. 2005;113(3):393-6, <http://dx.doi.org/10.1002/ijc.20573>.
 166. Sadeghi F, Salehi-Vaziri M, Ghodsi SM, Alizadeh A, Bokharaei-Salim F, Saroukalei ST, et al. Prevalence of JC polyomavirus large T antigen sequences among Iranian patients with central nervous system tumors. *Arch Virol*. 2015;160(1):61-8, <http://dx.doi.org/10.1007/s00705-014-2230-0>.
 167. Del Valle L, White MK, Enam S, Piña Oviedo S, Bromer MQ, Thomas RM, et al. Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal carcinoma. *Cancer*. 2005;103(3):516-27, <http://dx.doi.org/10.1002/cncr.20806>.
 168. Robles C, Viscidi R, Malats N, Silverman DT, Tardon A, Garcia-Closas R, et al. Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. *Int J Cancer*. 2013;133(3):597-603, <http://dx.doi.org/10.1002/ijc.28053>.
 169. Anzivino E, Rodio DM, Mischitelli M, Bellizzi A, Sciarra A, Salciccia S, et al. High Frequency of JCV DNA Detection in Prostate Cancer Tissues. *Cancer Genomics Proteomics*. 2015;12(4):189-200.
 170. Campello C, Comar M, Zanotta N, Minicozzi A, Rodella L, Poli A. Detection of SV40 in colon cancer: a molecular case-control study from northeast Italy. *J Med Virol*. 2010;82(7):1197-200, <http://dx.doi.org/10.1002/jmv.21798>.
 171. Polesel J, Gheit T, Talamini R, Shahzad N, Lenardon O, Sylla B, et al. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. *Br J Cancer*. 2012;106(1):222-6, <http://dx.doi.org/10.1038/bjc.2011.519>.
 172. Boltin D, Vilkin A, Levi Z, Elkayam O, Niv Y. JC virus T-Antigen DNA in gastrointestinal mucosa of immunosuppressed patients: a prospective, controlled study. *Dig Dis Sci*. 2010;55(7):1975-81, <http://dx.doi.org/10.1007/s10620-009-0986-y>.
 173. Selgrad M, Koornstra JJ, Fini L, Blom M, Huang R, Devo EB, et al. JC virus infection in colorectal neoplasia that develops after liver transplantation. *Clin Cancer Res*. 2008;14(20):6717-21, <http://dx.doi.org/10.1158/1078-0432.CCR-08-0961>.
 174. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. *Am J Transplant*. 2006;6(9):2000-5, <http://dx.doi.org/10.1111/j.1600-6143.2006.01403.x>.
 175. Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). *Adv Exp Med Biol*. 2006;577(1):19-45, <http://dx.doi.org/10.1007/0-387-32957-9>.
 176. Vanchiere JA, Nicome RK, Greer JM, Demmler GJ, Butel JS. Frequent detection of polyomaviruses in stool samples from hospitalized children. *J Infect Dis*. 2005;192(4):658-64, <http://dx.doi.org/10.1086/432076>.
 177. Kalvathev Z, Slavov S, Shtereva M, Savova S. Reactivation of Polyomavirus hominis 1 (BKV) during pregnancy and the risk of mother-to-child transmission. *J Clin Virol*. 2008;43(3):328-9, <http://dx.doi.org/10.1016/j.jcv.2008.08.002>.
 178. Barraclough KA, Isabel NM, Staatz CE, Johnson DW. BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. *J Transplant*. 2011;2011:750836, <http://dx.doi.org/10.1155/2011/750836>.
 179. Pollara CP, Corbellini S, Chiappini S, Sandrini S, De Tomasi D, Bonfanti C, et al. Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. *New Microbiol*. 2011;34(2):165-71.
 180. Pastrana DV, Ray U, Magaldi TG, Schowalter RM, Çuburu N, Buck CB. BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism. *J Virol*. 2013;87(18):10105-13, <http://dx.doi.org/10.1128/JVI.01189-13>.
 181. Bennett SM, Zhao L, Bosard C, Imperiale MJ. Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry. *Virology*. 2015;474:110-6, <http://dx.doi.org/10.1016/j.virol.2014.10.013>.
 182. Unterstab G, Gosert R, Leuenberger D, Lorentz P, Rinaldo CH, Hirsch HH. The polyomavirus BK agnoprotein co-localizes with lipid droplets. *Virology*. 2010;399(2):322-31, <http://dx.doi.org/10.1016/j.virol.2010.01.011>.
 183. Myhre MR, Olsen GH, Gosert R, Hirsch HH, Rinaldo CH. Clinical polyomavirus BK variants with agnogene deletion are non-functional but rescued by trans-complementation. *Virology*. 2010;398(1):12-20, <http://dx.doi.org/10.1016/j.virol.2009.11.029>.
 184. Johannessen M, Walquist M, Gerits N, Dragset M, Spang A, Moens U. BKV agnoprotein interacts with α -soluble N-ethylmaleimide-sensitive fusion attachment protein, and negatively influences transport of VSVG-EGFP. *PLoS One*. 2011;6(9):e24489, <http://dx.doi.org/10.1371/journal.pone.0024489>.
 185. Gerits N, Johannessen M, Tümmler C, Walquist M, Kostenko S, Snapkov I, et al. Agnoprotein of polyomavirus BK interacts with proliferating cell nuclear antigen and inhibits DNA replication. *Viol J*. 2015;12:7, <http://dx.doi.org/10.1186/s12985-014-0220-1>.
 186. Abend JR, Joseph AE, Das D, Campbell-Cecen DB, Imperiale MJ. A truncated T antigen expressed from an alternatively spliced BK virus early mRNA. *J Gen Virol*. 2009;90(Pt 5):1238-45, <http://dx.doi.org/10.1099/vir.0.009159-0>.
 187. Lipshutz GS, Mahanty H, Feng S, Hirose R, Stock PG, Kang SM, et al. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. *Am J Transplant*. 2005;5(2):366-73, <http://dx.doi.org/10.1111/j.1600-6143.2004.00685.x>.
 188. Burger-Calderon R, Madden V, Hallett RA, Gingerich AD, Nিকেleit V, Webster-Cyriaque J. Replication of oral BK virus in human salivary gland cells. *J Virol*. 2014;88(1):559-73, <http://dx.doi.org/10.1128/JVI.02777-13>.
 189. White MK, Khalili K. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. *Virology*. 2004;324(1):1-16, <http://dx.doi.org/10.1016/j.virol.2004.03.025>.
 190. Imperiale MJ. The human polyomaviruses, BKV and JCV: molecular pathogenesis of acute disease and potential role in cancer. *Virology*. 2000;267(1):1-7, <http://dx.doi.org/10.1006/viro.1999.0092>.
 191. Drop B, Strycharz-Dudziak M, Kliszczewska E, Polz-Dacewicz M. Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer. *Int J Mol Sci*. 2017;18(12): E2752, <http://dx.doi.org/10.3390/ijms18122752>.
 192. Fioriti D, Videtta M, Mischitelli M, Degener AM, Russo G, Giordano A, et al. The human polyomavirus BK: Potential role in cancer. *J Cell Physiol*. 2005;204(2):402-6, <http://dx.doi.org/10.1002/jcp.20300>.
 193. Wu JH, Nguyen HP, Rady PL, Tyring SK. Molecular insight into the viral biology and clinical features of trichodysplasia spinulosa. *Br J Dermatol*. 2016;174(3):490-8, <http://dx.doi.org/10.1111/bjd.14239>.
 194. Kazem S, van der Meijden E, Wang RC, Rosenberg AS, Pope E, Benoit T, et al. Polyomavirus-associated Trichodysplasia spinulosa involves hyperproliferation, pRB phosphorylation and upregulation of p16 and p21. *PLoS One*. 2014;9(10):e108947, <http://dx.doi.org/10.1371/journal.pone.0108947>.
 195. Nguyen HT, Hong X, Tan S, Chen Q, Chan L, Fivaz M, et al. Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene. *Cell Rep*. 2014;8(3):707-13, <http://dx.doi.org/10.1016/j.celrep.2014.06.062>.
 196. van der Meijden E, Kazem S, Dargel CA, van Vuren N, Hensbergen PJ, Feltkamp MC. Characterization of T Antigens, Including Middle T and Alternative T, Expressed by the Human Polyomavirus Associated with Trichodysplasia Spinulosa. *J Virol*. 2015;89(18):9427-39, <http://dx.doi.org/10.1128/JVI.00911-15>.
 197. Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. *Microbiol Mol Biol Rev*. 2009;73(3):542-63, <http://dx.doi.org/10.1128/MMBR.00009-09>.
 198. Ichaso N, Dilworth SM. Cell transformation by the middle T-antigen of polyoma virus. *Oncogene*. 2001;20(54):7908-16, <http://dx.doi.org/10.1038/sj.onc.1204859>.
 199. Wu JH, Narayanan D, Simonette RA, Rady PL, Tyring SK. Dysregulation of the MEK/ERK/MNK1 signalling cascade by middle T antigen of the trichodysplasia spinulosa polyomavirus. *J Eur Acad Dermatol Venereol*. 2017;31(8):1338-41, <http://dx.doi.org/10.1111/jdv.14326>.



200. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. *FASEB J*. 2008;22(4):954-65, <http://dx.doi.org/10.1096/fj.06-7859rev>.
201. Silverstein AM, Barrow CA, Davis AJ, Mumby MC. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. *Proc Natl Acad Sci U S A*. 2002;99(7):4221-6, <http://dx.doi.org/10.1073/pnas.072071699>.
202. Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. *PLoS One*. 2012;7(6):e38499, <http://dx.doi.org/10.1371/journal.pone.0038499>.
203. Schrama D, Buck CB, Houben R, Becker JC. No evidence for association of HPyV6 or HPyV7 with different skin cancers. *J Invest Dermatol*. 2012;132(1):239-41, <http://dx.doi.org/10.1038/jid.2011.261>.
204. Beckervordersandforth J, Pujari S, Rennspiess D, Speel EJ, Winnepenninckx V, Diaz C, et al. Frequent detection of human polyomavirus 6 in keratoacanthomas. *Diagn Pathol*. 2016;11(1):58, <http://dx.doi.org/10.1186/s13000-016-0509-z>.
205. Herberhold S, Hellmich M, Panning M, Bartok E, Silling S, Akgül B, et al. Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma. *Med Microbiol Immunol*. 2017;206(2):93-103, <http://dx.doi.org/10.1007/s00430-016-0486-6>.
206. Schrama D, Grosser L, Ugurel S, Hafner C, Pastrana DV, Buck CB, et al. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations. *JAMA Dermatol*. 2014;150(11):1180-6, <http://dx.doi.org/10.1001/jamadermatol.2014.1116>.
207. Arthur RR, Grossman SA, Ronnett BM, Bigner SH, Vogelstein B, Shah KV. Lack of association of human polyomaviruses with human brain tumors. *J Neurooncol*. 1994;20(1):55-8, <http://dx.doi.org/10.1007/BF01057961>.
208. Dörries K, Loeber G, Meixensberger J. Association of polyomaviruses JC, SV40, and BK with human brain tumors. *Virology*. 1987;160(1):268-70, [http://dx.doi.org/10.1016/0042-6822\(87\)90071-7](http://dx.doi.org/10.1016/0042-6822(87)90071-7).
209. De Mattei M, Martini F, Corallini A, Gerosa M, Scotlandi K, Carinci P, et al. High incidence of BK virus large-T-antigen-coding sequences in normal human tissues and tumors of different histotypes. *Int J Cancer*. 1995;61(6):756-60, <http://dx.doi.org/10.1002/ijc.2910610603>.
210. Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: innocent until proven guilty. *Semin Cancer Biol*. 2009;19(4):252-60, <http://dx.doi.org/10.1016/j.semcancer.2009.02.004>.
211. Loutfy SA, Moneer MM, Salem SE, El-Moniem Abada EA, El-Moniem Ahmed EA, Ibrahim LH, et al. Polyomavirus infections and its clinical relevance in cancer patients: A Prospective Study. *J Infect Public Health*. 2017;10(1):22-30, <http://dx.doi.org/10.1016/j.jiph.2016.01.008>.
212. Monini P, Rotola A, Di Luca D, De Lellis L, Chiari E, Corallini A, et al. DNA rearrangements impairing BK virus productive infection in urinary tract tumors. *Virology*. 1995;214(1):273-9, <http://dx.doi.org/10.1006/viro.1995.9928>.
213. Russo G, Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Giordano A, et al. p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? *J Med Virol*. 2008;80(12):2100-7, <http://dx.doi.org/10.1002/jmv.21312>.
214. Csoma E, Bidiga L, Méhes G, Gergely L. No Evidence of Human Polyomavirus 9, WU and KI DNA in Kidney and Urinary Bladder Tumour Tissue Samples. *Pathobiology*. 2016;83(5):252-7, <http://dx.doi.org/10.1159/000445120>.
215. Corbex M, Bouzbid S, Traverse-Glehen A, Aouras H, McKay-Chopin S, Carreira C, et al. Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from Algeria compared with other types of breast cancer tumors. *PLoS One*. 2014;9(12):e114559, <http://dx.doi.org/10.1371/journal.pone.0114559>.
216. Schmitt M, Höfler D, Koleganova N, Pawlita M. Human polyomaviruses and other human viruses in neuroendocrine tumors. *Cancer Epidemiol Biomarkers Prev*. 2011;20(7):1558-61, <http://dx.doi.org/10.1158/1055-9965.EPI-11-0424>.
217. Fioriti D, Pietropaolo V, Dal Forno S, Laurenti C, Chiarini F, Degener AM. Urothelial bladder carcinoma and viral infections: different association with human polyomaviruses and papillomaviruses. *Int J Immunopathol Pharmacol*. 2003;16(3):283-8, <http://dx.doi.org/10.1177/039463200301600315>.
218. Rogers R, Gohh R, Noska A. Urothelial cell carcinoma after BK polyomavirus infection in kidney transplant recipients: A cohort study of veterans. *Transpl Infect Dis*. 2017;19(5). Epub 2017 Sep 16. PubMed PMID: 28727230.
219. Völter C, Hausen H, Alber D, de Villiers EM. Screening human tumor samples with a broad-spectrum polymerase chain reaction method for the detection of polyomaviruses. *Virology*. 1997;237(2):389-96, <http://dx.doi.org/10.1006/viro.1997.8772>.
220. Ramqvist T, Nordfors C, Dalianis T, Ragnarsson-Olding B. DNA from human polyomaviruses, TSPyV, MWPyV, HPyV6, 7 and 9 was not detected in primary mucosal melanomas. *Anticancer Res*. 2014;34(2):639-43.
221. Gheit T, Muñoz JP, Levican J, González C, Ampuero S, Parra B, et al. Merkel cell polyomavirus in non-small cell lung carcinomas from Chile. *Exp Mol Pathol*. 2012;93(1):162-6, <http://dx.doi.org/10.1016/j.yexmp.2012.04.008>.
222. Gellrich S, Schewe C, Sterry W, Lukowsky A. Absence of SV40 and other polyomavirus (JCV, BKV) DNA in primary cutaneous B cell lymphomas. *J Invest Dermatol*. 2005;124(1):278-9, <http://dx.doi.org/10.1111/j.0022-202X.2004.23536.x>.
223. Haegglblom L, Franzén J, Näsman A. Human polyomavirus DNA detection in keratoacanthoma and Spitz naevus: no evidence for a causal role. *J Clin Pathol*. 2017;70(5):451-3, <http://dx.doi.org/10.1136/jclinpath-2016-204197>.
224. Teramoto S, Kaiho M, Takano Y, Endo R, Kikuta H, Sawa H, et al. Detection of KI polyomavirus and WU polyomavirus DNA by real-time polymerase chain reaction in nasopharyngeal swabs and in normal lung and lung adenocarcinoma tissues. *Microbiol Immunol*. 2011;55(7):525-30, <http://dx.doi.org/10.1111/j.1348-0421.2011.00346.x>.
225. Colombara DV, Manhart LE, Carter JJ, Hawes SE, Weiss NS, Hughes JP, et al. Absence of an association of human polyomavirus and papillomavirus infection with lung cancer in China: a nested case-control study. *BMC Cancer*. 2016;16:342, <http://dx.doi.org/10.1186/s12885-016-2381-3>.
226. Giraud G, Ramqvist T, Pastrana DV, Pavot V, Lindau C, Kogner P, et al. DNA from KI, WU and Merkel cell polyomaviruses is not detected in childhood central nervous system tumours or neuroblastomas. *PLoS One*. 2009;4(12):e8239, <http://dx.doi.org/10.1371/journal.pone.0008239>.
227. Csoma E, Bidiga L, Méhes G, Katona M, Gergely L. Survey of KI, WU, MW, and STL Polyomavirus in Cancerous and Non-Cancerous Lung Tissues. *Pathobiology*. 2018;85(3):179-85, <http://dx.doi.org/10.1159/000481174>.
228. Gustafsson B, Honkaniemi E, Goh S, Giraud G, Forestier E, von Döbeln U, et al. KI, WU, and Merkel cell polyomavirus DNA was not detected in Guthrie cards of children who later developed acute lymphoblastic leukemia. *J Pediatr Hematol Oncol*. 2012;34(5):364-7, <http://dx.doi.org/10.1097/MPH.0b013e318241fb52>.
229. Duncavage EJ, Le BM, Wang D, Pfeifer JD. Merkel cell polyomavirus: a specific marker for Merkel cell carcinoma in histologically similar tumors. *Am J Surg Pathol*. 2009;33(12):1771-7, <http://dx.doi.org/10.1097/PAS.0b013e3181ba7b73>.
230. Dworkin AM, Tseng SY, Allain DC, Iwenofu OH, Peters SB, Toland AE. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. *J Invest Dermatol*. 2009;129(12):2868-74, <http://dx.doi.org/10.1038/jid.2009.183>.
231. Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, et al. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. *Clin Cancer Res*. 2015;21(11):2624-34, <http://dx.doi.org/10.1158/1078-0432.CCR-14-2667>.
232. Joh J, Jensen AB, Moore GD, Rezazadeh A, Slone SP, Ghim SJ, et al. Human papillomavirus (HPV) and Merkel cell polyomavirus (MCPyV) in non small cell lung cancer. *Exp Mol Pathol*. 2010;89(3):222-6, <http://dx.doi.org/10.1016/j.yexmp.2010.08.001>.
233. Hashida Y, Imajoh M, Nemoto Y, Kamioka M, Taniguchi A, Taguchi T, et al. Detection of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer. *Br J Cancer*. 2013;108(3):629-37, <http://dx.doi.org/10.1038/bjc.2012.567>.
234. Kim GJ, Lee JH, Lee DH. Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer. *Medicine (Baltimore)*. 2017;96(3):e5413, <http://dx.doi.org/10.1097/MD.0000000000005413>.
235. Sastre-Garau X, Peter M, Avril MF, Laude H, Couturier J, Rozenberg F, et al. Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. *J Pathol*. 2009;218(1):48-56, <http://dx.doi.org/10.1002/path.2532>.
236. Fava P, Merlino C, Novelli M, Ponti R, Galliano I, Montanari P, et al. HPyV6, HPyV7 and TSPyV DNA sequences detection in skin disease patients and healthy subjects. *J Eur Acad Dermatol Venereol*. 2016;30(4):624-7, <http://dx.doi.org/10.1111/jdv.13094>.
237. Wu JH, Simonette RA, Nguyen HP, Rady PL, Tyring SK. Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: Protein phosphatase 2A targeting and MAPK cascade activation. *Journal of Medical Virology*. 2017;89(4):742-7, <http://dx.doi.org/10.1002/jmv.24688>.